%PDF-1.4%âãÏÓ
62 0 obj
<</Metadata 64 0 R/PageLabels 10 0 R/Pages 55 0 R/Type/Catalog>>
endobj
64 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2008-01-23T14:58:47Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2015-04-18T04:36:43-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2015-04-18T04:36:43-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:e3270548-1dd1-11b2-0a00-1e0a273dd000</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e327054c-1dd1-11b2-0a00-09f600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
10 0 obj
<</Nums[0<</S/D/St 278>>]>>
endobj
55 0 obj
<</Count 6/Kids[56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R]/Type/Pages>>
endobj
56 0 obj
<</Annots 65 0 R/Contents 66 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 67 0 R/GS2 68 0 R>>/Font<</T1_0 14 0 R/T1_1 18 0 R/T1_10 69 0 R/T1_2 22 0 R/T1_3 26 0 R/T1_4 30 0 R/T1_5 34 0 R/T1_6 38 0 R/T1_7 42 0 R/T1_8 46 0 R/T1_9 50 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
57 0 obj
<</Annots 70 0 R/Contents 71 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 72 0 R/GS2 73 0 R>>/Font<</T1_0 34 0 R/T1_1 14 0 R/T1_2 22 0 R/T1_3 18 0 R/T1_4 38 0 R/T1_5 30 0 R/T1_6 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
58 0 obj
<</Annots 74 0 R/Contents 75 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 76 0 R/GS2 77 0 R>>/Font<</T1_0 34 0 R/T1_1 38 0 R/T1_2 14 0 R/T1_3 18 0 R/T1_4 22 0 R/T1_5 54 0 R/T1_6 30 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
59 0 obj
<</Annots 78 0 R/Contents 79 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 80 0 R/GS2 81 0 R>>/Font<</T1_0 34 0 R/T1_1 38 0 R/T1_2 14 0 R/T1_3 54 0 R/T1_4 22 0 R/T1_5 18 0 R/T1_6 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
60 0 obj
<</Annots 82 0 R/Contents 83 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 84 0 R/GS2 85 0 R>>/Font<</T1_0 34 0 R/T1_1 14 0 R/T1_2 38 0 R/T1_3 30 0 R/T1_4 18 0 R/T1_5 22 0 R/T1_6 54 0 R/T1_7 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 86 0 R/Contents 87 0 R/MediaBox[0 0 612 792]/Parent 55 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 88 0 R/GS2 89 0 R>>/Font<</T1_0 54 0 R/T1_1 22 0 R/T1_2 18 0 R/T1_3 14 0 R/T1_4 34 0 R/T1_5 69 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
86 0 obj
[90 0 R]
endobj
87 0 obj
<</Length 12519>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 347.0937 749.5293 Tm
(Prolonged QT Interval, Syncope, and Delirium with Galantamine)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(283)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 135.941 492 602.059 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.008 Tc 0.008 Tw 8 0 0 8 73.5 732.5292 Tm
(head-up tilt testing and the additional yield of drug provocation. Heart\)Tj
-0.02499 Tc 0 Tw 0 -1.25 TD
[(1996;76:406)-25 (-1)35 (1.)]TJ
-0.004 Tc 0.004 Tw -1.6875 -1.375 Td
[(21.)-496 (Bordier P)110 (, Lanusse S, Garrigue S, et al. Causes of syncope in patients)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.25 Td
[(with Alzheimer)-35 (\325)56 (s disease treated with donepezil. Drugs Aging 2005;22:)]TJ
-0.02499 Tc 0 Tw T*
(687-94.)Tj
-0.015 Tc 0.015 Tw -1.6875 -1.375 Td
[(22.)-485 (Bednar MM, Harrigan EP)110 (, Anziano RJ, Camm AJ, Ruskin JN. The QT)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(interval. Prog Cardiovasc Dis 2001;43:1)50 (-)-125 (45.)]TJ
0 Tc 0.02499 Tw -1.6875 -1.375 Td
[(23.)-500 (Martins JB, Zipes DP)110 (, Lund DD. Distribution of local repolarization)]TJ
-0.02499 Tc 0.006 Tw 1.6875 -1.25 Td
[(changes produced by ef)20 (ferent vagal stimulation in the canine ventricles. J)]TJ
0.013 Tw T*
[(Am Coll Cardiol 1983;2:1)35 (191)50 (-9.)]TJ
-0.002 Tc 0.002 Tw -1.6875 -1.375 Td
[(24.)-498 (Inglis F)80 (. The tolerability and safety of cholinesterase inhibitors in the)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
[(treatment of dementia \(letter\). Int J Clin Pract Suppl 2002;Jun:45)-25 (-)-75 (63.)]TJ
-0.035 Tc 0.008 Tw -1.6875 -1.375 Td
[(2)-10 (5)-10 (.)-485 (Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob\-)]TJ
0.013 Tw 1.6875 -1.25 Td
[(ability of adverse drug reactions. Clin Phar)-25 (macol Ther 1981;30:239)-25 (-)-125 (45.)]TJ
ET
0 0 0 1 K
114 575.029 m
240 575.029 l
S
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 9 0 0 9 60 550.5292 Tm
[(Prolongaci\227n del Intervalo QT)75 (, S\222ncope, y Delirio con el uso de la)]TJ
0 Tw 0 -1.22223 TD
(Galantamina)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 60 525.5292 Tm
(AA Fisher y MW Davis)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 60 509.5293 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 121.9947 509.5293 Tm
[(2008;42:278)-25 (-)-25 (83.)]TJ
ET
BT
/T1_4 1 Tf
7.5 0 0 7.5 60 484.0293 Tm
(EXTRACT)Tj
0 Tc 4.41532 0 Td
(O)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 60 470.5293 Tm
(OBJETIV)Tj
-0.02299 Tc 4.19462 0 Td
(OS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 96.7354 470.5293 Tm
(Describir un caso de prolongaci\227n del intervalo QT)Tj
-0.0251 Tc 19.33697 0 Td
(,)Tj
-0.02499 Tc 0 Tw 0.46237 0 Td
(s\222ncope,)Tj
-0.0251 Tc -24.12115 -1.11765 Td
(y)Tj
-0.02499 Tc 0.01199 Tw 0.7123 0 Td
(delirio asociado al uso de la galantamina, y analizar casos similares)Tj
-0.03999 Tc -0.7123 -1.11765 Td
(reportados al Comit\216 Consejero de Reacciones Adversas a Medicamentos)Tj
-0.02499 Tc 0 -1.11764 TD
(Australiano, con el uso de los inhibidores de la acetilcolinesterasa.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 60 429.5293 Tm
(RESUMEN DEL CASO:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 123.6132 429.5293 Tm
(Un paciente de 85 a\226os de edad con historia de)Tj
-7.48391 -1.11765 Td
(demencia leve de etiolog\222a mixta \(Alzheimer y vascular\) hab\222a es\tado)Tj
T*
(recibiendo galantamina de liberaci\227n prolongada en dosis de 8 mg)Tj
0 -1.11765 TD
[(diarios por un a\226o y medio. T)35 (res meses antes de su admisi\227n a la sala de)]TJ
0 Tw 0 -1.11764 TD
(emer)Tj
0.01199 Tw 1.87827 0 Td
(gencia, el paciente hab\222a tenido un episodio de s\222ncope con baja d\e)Tj
-1.87827 -1.11765 Td
(presi\227n arterial y bradicardia. Dos meses m\207s tarde, la galantamin\a fue)Tj
0 -1.11765 TD
(suspendida pero en el transcurso de 2 semanas, el paciente present\227)Tj
0 -1.11764 TD
(marcado deterioro cognitivo, de comportamiento, y funcional por lo que)Tj
0 -1.11765 TD
[(la galantamina fue recetada de nuevo al paciente. T)36.4 (res semanas m\207s)]TJ
T*
(tarde, el paciente desarroll\227 s\222ncope, delirio, hipotensi\227n, pr\olongaci\227n)Tj
0 -1.11764 TD
(del intervalo QT con arritmias card\222acas serias, adem\207s de v\227mi\to y)Tj
0 -1.11765 TD
[(diarrea. Su contaje sangu\222neo y bioqu\222mico era nor)-23.9 (mal y no hab\222a)]TJ
T*
(indicio de infecci\227n. La galantamina y el irbesartan fueron suspendid\os.)Tj
0 -1.11764 TD
(En 6 d\222as su delirio se resolvi\227 completamente, y en 4 d\222as el \intervalo)Tj
0 -1.11765 TD
(QT se acort\227 de 503)Tj
0 Tc 7.73245 0.00001 Td
(\320)Tj
-0.02499 Tc 0.62491 0.00001 Td
[(443 milisegundos \(corregido con la f\227r)-24 (mula de)]TJ
-8.35735 -1.11766 Td
[(Bazett\), y per)-25 (maneci\227 en un valor nor)-25 (mal desde entonces.)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 60 274.5292 Tm
[(REPOR)37 (TES AUSTRALIANOS:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 142.0802 274.5292 Tm
(La galantamina estuvo asociada a 18 casos de)Tj
-9.65649 -1.11764 Td
(delirio/confusi\227n, 8 de s\222ncope, 13 de bradicardia, 6 de otro tipo\ de)Tj
0 -1.11764 TD
[(arritmias o anor)-25 (malidades en la conducci\227n, y 6 de hipotensi\227n. El)]TJ
0 -1.11765 TD
(donezil estudo asociado a 56, 15, 26, 15, y 5 casos, y la rivastigmina a\)Tj
0 -1.11764 TD
(21, 8, 6, 2, y 2 casos, respectivamente. Cinco de los casos reportados)Tj
T*
[(con la galantamina fueron fatales, 1)35 (1 con el donepezil, y 3 con la)]TJ
0 -1.11765 TD
(rivastsigmina, incluyendo 3, 6, y 0 casos de muerte repentina,)Tj
0 Tw 0 -1.11764 TD
(respectivamente.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 60 195.5293 Tm
(DISCUSI\356N:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 95.8463 195.5293 Tm
(Este caso junto con otros reportados previamente y los)Tj
-4.21721 -1.11765 Td
(identificados mediante la base de datos australiana ilustran que los)Tj
T*
(inhibidores de la acetilcolinesterasa pueden conllevar a delirio, s\222n\cope,)Tj
T*
(hipotensi\227n, y arritmias serias. La escala de probabilidad Naranjo in\dic\227)Tj
0 -1.11765 TD
(que la galantamina era probablemente responsable por la prolongaci\227n)Tj
0 -1.11764 TD
[(del intervalo QT)75 (, s\222ncope, y delirio en este paciente.)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 732.1874 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 368.0652 732.1874 Tm
(La)Tj
-0.02499 Tc 0.01199 Tw 1.2422 -0.00001 Td
(administraci\227n de la galantamina y otros inhibidores)Tj
-7.13222 -1.11764 Td
(de la acetilcolinesterasa requieren de la vigilancia y evaluaci\227n de)Tj
T*
(factores de riesgo que puedan precipitar una prolongaci\227n del interva\lo)Tj
0 -1.11765 TD
[(QT)75 (, s\222ncope, y delirio.)]TJ
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 439.675 687.1874 Tm
[(T)35 (raducido por Encar)-25 (naci\227n C Su\207rez)]TJ
ET
BT
/T1_4 1 Tf
0.01199 Tw 9 0 0 9 318 661.1874 Tm
[(Prolongation de l\325Intervalle QT)75 (, Syncope, et Delirium Suite \210 la)]TJ
0 -1.22223 TD
(Prise de Galantamine)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 318 636.1874 Tm
(AA Fisher et MW Davis)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 318 620.1873 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 379.9947 620.1873 Tm
[(2008;42:278)-25 (-)-25 (83.)]TJ
ET
BT
/T1_4 1 Tf
-0.0251 Tc 7.5 0 0 7.5 318 594.6874 Tm
(R)Tj
-0.02499 Tc (\203SUM\203)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 318 581.1874 Tm
(OBJECTIF:)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 350.6682 581.1874 Tm
(D)Tj
-0.02499 Tc 0.01199 Tw [(\216crire un cas de prolongation de l\325intervalle QT)75 (, de syncope,)]TJ
-3.84332 -1.11765 Td
(et de delirium li\216s \210 la prise de galantamine et comparer \210 d\325\autres cas)Tj
0 -1.11764 TD
[(rapport\216s au Comit\216 australien d\325ef)20 (fets ind\216sirables des m\216dicaments)]TJ
T*
[(concer)-25 (nant les inhibiteurs de l\325ac\216tylcholinest\216rase \(AchE\). )]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 540.1874 Tm
(SOMMAIRE DU CAS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 377.7539 540.1874 Tm
[(Un homme de 85 ans souf)20 (frant de d\216mence a \216t\216)]TJ
-7.02987 -1.11765 Td
(trait\216 par la galantamine \210 lib\216ration prolong\216e \210 raison\ de 8 mg par jour)Tj
T*
[(pendant 18 mois. T)34.8 (rois mois avant la pr\216sente hospitalisation, il a)]TJ
0 -1.11763 TD
(pr\216sent\216 un \216pisode de syncope avec hypotension et bradycardie.\ Deux)Tj
0 -1.11765 TD
(mois plus tard, la galantamine a \216t\216 cess\216e mais en moins de 2 \semaines,)Tj
0 -1.11764 TD
(le patient a pr\216sent\216 une d\216t\216rioration marqu\216e au niveau\ fonctionnel,)Tj
0 -1.11765 TD
(comportemental, et cognitif ; la galantamine a donc \216t\216 r\216intro\duite.)Tj
0 -1.11764 TD
[(T)35 (rois semaines suite \210 la r\216introduction de la galantamine, le pati\ent a)]TJ
T*
(fait une syncope avec hypotension, un delirium, une prolongation de)Tj
0 -1.11765 TD
[(l\325intervalle QT)75 (, et de graves arythmies cardiaques en plus de)]TJ
0 -1.11764 TD
[(vomissements et de diarrh\216e. \313 l\325admission, la for)-23.2 (mule sanguine et tous)]TJ
0 -1.11765 TD
[(les tests de biochimie \216taient nor)-25 (maux. Aucune infection n\325a \216t\216)]TJ
T*
(d\216tect\216e. La galantamine ainsi que l\325irb\216sartan ont \216t\216\ cess\216s. Le)Tj
0 -1.11764 TD
(delirium est compl\217tement disparu apr\217s 6 jours et l\325intervalle\ QT est)Tj
T*
(pass\216 de 503)Tj
0 Tc 4.88416 0 Td
(\320)Tj
-0.02499 Tc 0.6249 0 Td
[(443 millisecondes \(corrig\216 selon la for)-23.3 (mule de Bazett\) 4)]TJ
-5.50906 -1.11765 Td
[(jours apr\217s l\325arr\220t de la galantamine et est demeur\216 nor)-25 (mal par la suite.)]TJ
T*
(La galantamine a \216t\216 associ\216e \210 18 cas de delirium ou de con\fusion, 8)Tj
-0.0251 Tc 0 -1.11765 TD
(cas)Tj
-0.02499 Tc 1.43918 0 Td
(de syncope, 13 cas de bradycardie, 6 cas d\325arythmies ou de troubles)Tj
-1.43918 -1.11765 Td
(de conduction, et 6 cas d\325hypotension. Le don\216p\216zil a, quant \210\ lui, \216t\216)Tj
0 -1.11764 TD
(associ\216 respectivement \210 56, 15, 26, 15, et 5 cas tandis que la)Tj
0 -1.11765 TD
(rivastigmine l\325a \216t\216 dans 21, 8, 6, 2, et 2 cas respectivement.\ Cinq cas de)Tj
T*
[(d\216c\217s ont \216t\216 rapport\216s avec la galantamine, 1)35 (1 avec le don\216p\216zil, et 3)]TJ
0 -1.11764 TD
(avec la rivastigmine, incluant 3, 6, et 0 morts soudaines respectivement\. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 318.6874 Tm
(DISCUSSION:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 357.0317 318.6874 Tm
(Ce cas, en plus des cas pr\216c\216demment publi\216s et de ceux)Tj
-4.59196 -1.11764 Td
(rapport\216s dans le cadre du programme australien de d\216claration des\)Tj
0 -1.11765 TD
[(ef)20 (fets ind\216sirables des m\216dicaments, montre que les inhibiteurs de)]TJ
0 -1.11764 TD
(l\325AchE peuvent provoquer un delirium, une syncope, de l\325hypotensio\n,)Tj
T*
[(et des arythmies potentiellement mortelles. L)90 (\325\216chelle de probabilit\216 de)]TJ
0 -1.11765 TD
(Naranjo montre que la galantamine \216tait la cause probable de la)Tj
0 -1.11764 TD
[(prolongation de l\325intervalle QT)75 (, de la syncope, et du delirium observ\216s)]TJ
0 -1.11765 TD
(chez ce patient. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 239.6873 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 239.6873 Tm
(La prise de galantamine et d\325autres inhibiteurs de)Tj
-5.43686 -1.11764 Td
(l\325ac\216tylcholinest\216rase doit \220tre suivie rigoureusement et un\e \216valuation)Tj
T*
(des facteurs de risque pouvant pr\216cipiter une prolongation de l\325in\tervalle)Tj
0 -1.11764 TD
[(QT)75 (, une syncope, ou un delirium doit \220tre faite. )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 8 0 0 8 468.1624 194.6873 Tm
(T)Tj
-0.02499 Tc 0.013 Tw 0.55068 0.00001 Td
(raduit par Denyse Demers)Tj
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
54 0 obj
<</BaseFont/HBYZVQ+Times-BoldItalic/Encoding 51 0 R/FirstChar 32/FontDescriptor 53 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 722 0 667 722 0 389 0 0 0 889 0 0 611 722 0 556 611 0 0 889 0 0 0 0 0 0 0 0 0 500 0 444 500 444 0 500 556 278 0 0 278 778 556 500 500 0 389 389 278 556 444 667 0 444]>>
endobj
22 0 obj
<</BaseFont/AOGMZT+Times-Italic/Encoding 19 0 R/FirstChar 32/FontDescriptor 21 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 0 500 0 500 0 0 0 500 0 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
18 0 obj
<</BaseFont/CLWRCQ+ZapfDingbatsITC/Encoding 15 0 R/FirstChar 110/FontDescriptor 17 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
14 0 obj
<</BaseFont/OHABFE+Times-Bold/Encoding 11 0 R/FirstChar 32/FontDescriptor 13 0 R/LastChar 251/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 942 721 776 610 0 721 555 666 721 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 776 0 0 0 0 0 0 0 0 0 0 0 0 332]>>
endobj
34 0 obj
<</BaseFont/PWMQHS+Times-Roman/Encoding 31 0 R/FirstChar 32/FontDescriptor 33 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 564 0 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 333 0 333 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 0 0 0 0 0 444 444 444 0 278 0 0 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 500 0 444 444 333 333]>>
endobj
69 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
31 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 63/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/bracketleft 93/bracketright 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave 142/eacute/egrave/ecircumflex 146/iacute 150/ntilde/oacute 203/Agrave 208/endash 210/quotedblleft/quotedblright/quoteleft/quoteright]/Type/Encoding>>
endobj
33 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 32 0 R/FontName/PWMQHS+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
32 0 obj
<</Length 9986/Length1 9986/Subtype/Type1C>>stream
  PWMQHS+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹   û   ÷  ²¬  &á }ˆ002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  Z  D F U Z M I P J O T S B  C 	 " $ * 
 V E N G  [   5 H Q W X  Y 1 L 4 2 8 % 3   )      ' . &  (    6 0  / R K 9 - #   i w :  + 7 ,   < > A ; Ø Ó Ï × È o Ë ² ® Ò Ğ \   O ­ ùq©\·,»(¶¹Yº#Z›}/Œ£â		5	
K
Ù:Ò—’,Œúe¶ïiÎ1Ÿ	†¡‡´ğV­|ÜI´I.Q­|ê#kÇK·à
?~ğZã ¢![!r")"Õ#f#í$sûbÓø¨¤×ø0÷(}“`HapQ‹1Kİ÷ğÄÔØ²–‚c—‘w•kš|£‹¦¥ÁEº<û+!û!ûÚ/÷ßÆº÷ÀûbĞ÷o«÷¯¤ĞFÒ÷cñôø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½ìû÷-ûcÙš®¯ÇÆ¥m7—ü¿ø«Ğß÷ªÍ~–vrzt‹g|¦Ê÷³ğ«&÷–‰…U<midp„†‰ˆ‹…‹‡Œ‰‹¿ûÂ5©bÉ¸²¤¾¬û*ûmğøËw™ø`ønøI™û}¯ˆ—„z„”qB<ûqû÷‚‹’‹–œ’’½‘™ûa}¨†—„”w÷ûŠ¦P®J|tpG{rt|z||wuloxzpkªr´Òµ¼÷*Ä÷/ø-–©™˜¡ü vìß÷”›MŒ~—Ãøç‡Hwv…Ey{Œ™’‹—°“€YüpV{}N‡{û* vø+ÁÓß÷Nßøz›X‚—Ğ÷[öaÀ9R_rQ`‰÷Â…\{˜ kzŒ“‘‹°“‚aükF‚U†{÷k›T~œÎ÷…¹µ«±º¦eFûZG€}R‡{û*‚¦ø4§¨ä÷šäøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûü vø^w÷$ğ×ğ8ßğ÷Eù§t¢opttop¡t§§¢¢¦Öı›èK–Ó÷÷†WwZyVy|©Œ‹“¦”{_û{CGˆ{û* vø)ÂŒwÚÜ:ß÷EßÔøx›]}›¼÷yè^ÄB[p|IDÛ¬„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ì»Ã›”¬»£kJûeN}xZˆ{û™‚¡vøZw’¢¾È÷:Ñœ÷ğ÷»t«M° Ënœ|¤‹©¯­¨¶Å®d6œ›¬‡÷ƒ†‡‰…†„Œ…œ™cs:QXDOªeáZÅj­xq‹n_koYEi¯òs{\û/˜”’”“•Šˆ–œ´¤‡¥ÙÊÄÓûÑ vø`w wÖßĞ÷âø+¬wŸhblsH]‰ä°†Jqw„Mu{š“Œ•¤•{_ûY‚ƒN{÷ƒ›KvÄ÷sœ˜¤™˜™“”’“‡ƒ”x “‡›¡›¥ûb–vŒÄø¤°ã÷6İxøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½¸T‘x·ª§›­§û0ßsˆ€ƒx{yb{sfo­¹Èºµ÷±ü$û*«øËÏß÷wäøh÷‡÷?è$SWlXp‰÷Á†a{U{[~{Œ•’‹®”cüœmãiÚ÷ò÷÷!2bû	]L5[\££÷¶µ¬Ä×¿;ûûÑû1vùêw»à÷Äû6ûáZ÷÷l÷[¶ñ÷î‚›û@û@û‹ûLûµ#ë%²a§t²tÓ‹÷[´ø4wšùGùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§œ}·øOv÷M²§÷ù÷yœ=AOp5‹û+,÷÷K÷Så÷	÷(öÒNû°¡‚÷tvƒu|wŒŒ{x’b™Y“a‹ûZ‹û!û#‹û]‹ûf÷û÷_‹÷‹÷ ¿¾×ûÑ‹ù÷ñ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆwûÑû1vùêw÷\à÷±÷Š÷aó+ñdµo¢d¢{÷5¼ûûlû[`%û(”{÷@÷Ö÷‹÷Lû*Äø(wÑß÷Fß=Ùèør¯™YŠ–º÷ìû2{ğË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦è·¶9ˆÙ§”¾™û*¿ø§¦á÷wßøµ›ƒ‚Š‹‡f‚—¸øË†Ux|‡=v{Œ˜‘‹¯“‚aû0¬cr•bû.ûûû×2÷Àµ ¶ªNˆÙ§oë­û+Èm^l_9SŞ÷÷¾×ÔÂ»\U÷ vø-¿Œwáß÷Lß÷KŞÜù™›RŒ•»÷c÷dÆ=SXpSUÅxk¤Sbv‚XF†‡ƒ†ƒÖ¼ƒZyŒ‹1py›Œ–¤•x^û’V}}S‰{÷r›Yy™°÷¯••—•Ü£¨«—ª»¡iCûmU~Sˆ{÷s›SŒ|œÈ÷¸«ªœºÁn9ûgS„ƒP„{ûÑ vø7«÷_¨òß7Şğøù«\§UûQAû2Š:kÜûÏB€B‡{÷˜›:–Ö÷Ï÷«èû÷Æ§² ”…oŸk¡”„œ¢¢ûÑ v÷UË²÷Š÷±÷UËûŠKûb‹©ø©¦øø6÷yv*|~/‹û÷¢ø*šûïˆûœÕ•™šÈ÷ûü*|øûÑÚ÷ ÷oøŞ¿h²\jrskk¢w¯”–‹“”Œ‘†Š‰hohVg•wÎ­¸ÈÅü$€÷Ñ÷÷I·ªr¤mlrrlm¤rª©¤¤©d‹øí¶Ÿ¡÷gñ÷|vøãø„÷>üÄ„û>¤÷¡ ›÷Áü’@~8ˆw÷ºŸ8~—Öø’Á÷ {û¡û*ûnÄ÷&Ö@Ôæ¤÷k²§§ĞnŞ÷EÙ¥¨İÀøiø²?u~“w]tm*AE-L¤hĞgCKyvtuš|²{¾ÀFZnfgTØ`ï÷÷ÙæÊ]´@ûTs•‹”˜™˜—˜™“”œ†¨çÏÍä¨‡|°PûSnf_İÀMaÌíÈ¦®»Ä¸B.óûŞR?bûŞÀ3M©µ£•œ²¹¬„›‰¤ˆ»‰À‰ğˆ¡€‹iû*ûVv÷a«øÇŒwÕß÷vàìøi÷ˆ÷Fä*R_sVa‰ÔÜ…TvŠŠ4m{Œ—‹—«‘[ügU„„M„{÷…›AŒ}—É÷0m«©²÷æ÷÷$6fûYAArm—s}—‚—•÷Šì¯“»ªºÕ¼>ûû*’vøewø\øoøG›û{«Šš€v|‚oy]=û[%÷”†˜‡œ‹’œ˜”¬›ûW{ŸŠ•†—¤s÷û¿£N‚˜e”‹’‹’·÷÷Ô¦Î’”©Ó’v¡vødw ù4pùIøG›û{ªˆ˜y~‡u~l0ûr<÷ktÉ„‹˜£™“¶›û^{µŠ™v­%/û\kâH÷C‹†›Š“’Ÿ˜”¬›ûG{¢Š”€ŸX÷ûék˜‘’‘‘”©™÷÷ƒåû°^œ‹Œ’“ŒŒ»÷÷îœµ’ü$›v£vÃ÷  ÷X–¿h²\jrskl¢w¯`™‹”•‡Š‰iogVg•xÎ­¸ÈÄû* vøWwœøbøs›hy˜n·û÷Xß÷¦§›­Œšû3}¬‡’‡}~uU?~Ÿ…s³xª„š‹“‹›•‘«™ûb}µŠ‡°Sêû%ûû9pd}lŠ{÷%›n€—“—™¡Û÷Üû›s‹Š‹€{€„r‡{-‹÷¡³÷½±xîò$ñ÷{÷Úø±øw÷$Ñû3ûšwÕƒ“‚DüFCŠp9‰w÷¬Ÿ<Œ|šÕ÷HŠ¤¢ŠÚÅ–¡²È­®ÇÏû‰!S\ûæz‹t÷™§’‘­÷ÍY-û* vİßø›`i¡d¼û.÷V¨¦ïè½®Ì‰™û_}“Š‹¢Š”‡Œ~Œƒƒ{|ûû‰ø3†Oxz†>w{Œ˜•‹’¯”ZüuU‰‰B€{÷~›M~”´÷I÷ûLr‡‹…ƒ‚…y{-~¯øø´Ñá÷~ïø~÷<Û\ÄûÕQ­"¼ÜÀµ²ÆåĞLû ¦¤u÷hvs…‚z„|}ŸOw‘q"?D)9­a÷C÷>¬hNGZ\C0MÀ÷Wu©ûh  –—¯«jç÷
ãØóÓûF÷Gwù¯­÷ø?÷ùPûEûŒ=¶5÷ ÷2¥ò÷‹÷E‹÷_û÷#ûS‹ûT‹ûû#‹û_‹ûÁûâS®u©}¥…¹T=Í÷_÷,’Œ‹Œ²ûøûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûR÷º–vù"ú1ú6ùŸûZwÂ†™‚l|„k‚sûûèû÷épĞ‹Š‹—¤¡•ÂŸûŸwÊ‡‡­:­9 û¯û%øƒ ˆ•‹˜¡—‘ÀŸûˆwÉ‚‡ÒûSÌûC†èû¡š÷.ø;‘y‘|‚‘|¡Uª;±*œ[ª4™Ù÷ƒ–ªÌ÷H¦Ôš³–©šµ›—»‘Ó‹x°øá°xòñø÷œù?÷â÷bû)÷ûû wÕ‡˜~CüQC~~A‡w÷¯÷‚÷&÷÷clû…ûU#)ûa\~”«ø­”‘Á÷Q÷	ûûLœ‹÷Á¤÷®¯xññ÷}÷Üù'Ÿdv—p¬ûb÷‘÷¢ÄÀè÷/Êû7û§wÔ†—~DüD4…„=ƒw÷¨Ÿ=’—Ò÷XÃ÷‚ûÉNø"Kcû=Š÷Šì¨—’½÷Å]1û*~§ù§ÃÖFÕ÷oĞT×ÔøQ÷0Øi»ûæØîÁ®µÎŞCÅ#!;H0J¢iñ4äû<ulG&ØI÷	÷
ØÍòØ1øPuiCVT¯E¿ÔÄ¸³ÊÏ¶_Gä™ü-G__IAUÇİÎ±É¾ªt”„‹èE£rNû*~°øâàÙ÷ùÑøJù?‚‘yuƒ‡w‹ûeûû€Š‰Šˆ‹‰‡‰‘Š÷ƒ÷5Yû.&O?;u„«^¡l}pr}~tb·uİ÷5÷ ò÷.÷@ûÄû)¦µà÷XœŒ’Ó‹÷¼·÷±õñ÷ÃñùPŸA~˜ÓøQÓ˜˜ÕŸû¨wÕ‡˜~CûWûÃ÷WÓ˜˜ÕŸû¨wÕ‡˜~CüQC~~A‡w÷¨ŸA~˜Ó÷b÷ÃûbC~~A‡wû*‹×ø¤Ô÷åáøn÷~md†pP‹û„÷=÷Dâæ³Ú‹Úí:Ù&ûHKûlŸ†¯ê²¯Ó‹İÄP6?\*95ûFûP~øû* v÷iáøš=Œy–ºøí‚ûG0~¥•œ’œ”‹¢•}jüm\y€=Š|û*}¯øçÆ÷ÑÚgÒĞøC÷lêk¹+·àÏ¹¤°ÅÚKÂ/,MXûdš‡³Ö¸«Ê‹Ì¸^L^r_cnpwvWyÁ¦†zªĞ»p¨XO8QICqv“ h£c‚ys}~ug·vÖ÷1÷ë÷û*}§øº÷‚š­ç÷‘äøh÷m÷Bßû[w„eLª÷1îê÷;«‡šûv‡ûMû;ûûDäû÷÷áê÷2jû cME4Sé÷'²­”™¡˜·´å¾Cûû*~¥ù¥£ë÷˜ëøp÷ß÷c÷EÆ¤nd˜[[d~rnFPbûûû³ûÑOr¨²~»»²˜¤¨ÑÇ³÷÷+ûh`!44`õ÷h÷i¶õââ¶!ûi-‹÷Èµb´÷“²xîğ÷”¢´¢Ïøµøœˆ÷#ü¦wÕ‡˜~CüQC~~A‡w÷«Ÿ@{šÒ÷p÷&‰ßŠ–š7¢÷|t6|8û&÷q·¨§÷÷~0÷ƒ‹ùö·øœğùïŸFyĞøQÓ™™ÔŸû[ûoüû{øûZwİ†˜~Dü+&|x;„w÷}Ÿ@x¥íø$÷ü·™÷øÎüV9€~<†wd‹±e÷Èµb´÷“²xîğ÷œ¢¬¢«€øè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥W€wÕ‡˜~CüQC~~A‡wø¯ü’vùFw‚÷º÷±ù8IûxıFÎÓ}³÷É÷®³«÷øëùW÷ãû’xÙ‡•@û4iOq?û3'÷
÷O÷Kì÷÷%ôĞUûµ£ƒ÷fuu„{€s…€€¡Ej‘\û[û"û&ûbû|÷A!÷K÷÷Â÷\Å™šÃû*‰w÷—¶ø§©ç÷€ï+ëôø^ø!÷5/÷
ûû4'û û
Ô:öÀ»±¹øŒˆmû%ûû>qw÷…›÷3÷<‹÷ô+bv‡‚uod}j>\Õ÷÷±ÊÏä¸4û;û*™vøèÔŸø@øTùšü|_`%œƒ²Ì¢›Á‹÷mûZüèÌû* v÷;ËøQw÷·Ú>Øèøk÷;Ë&øQ_ûÎüQK÷­û;Ø÷;ğ<Ëû„÷‚÷éÓ}·øúòò÷ü¶ùSùŸû{wÖ‰r(û¢=`slakTtJO\®nn®‚°Û÷ÔÔ––ÚŸû®yÚƒ•BûËû@İ6÷:÷HÙİ÷P÷™ğ› ÙÓ}¯øş¯­÷ø?÷ùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûR÷K“v˜ª÷—®š«÷g¤ÏwÈ×÷r¤ÌÖ÷q¥Àù—÷šÑf³Hûû ûû;»WÕóë÷÷ûø2eYYbyDd{’ oŸr{‘oû û	ûB¾QÍõï÷÷™‰–‡ƒ£—‰£·§’ °‰¿ÀûğıºÀø…÷£û:û<du¥·ÏË÷?â²ªf^ü÷¼û:û<cu£¸È°æ¹½£¡¡˜œ‘Š„’•š„¨ƒ‘w‹}Ó•v–ù÷ ¸ø1·xùTùŸû~wå„‘k4ûã‰üøuû?w¶Œ–„µ[üM%~y8ƒw÷Ÿ>z£ğø¸øJü¹œø¤ïšŸÚ‘û*ûVv÷aÉø§£à÷|ßø|ûk›]zš´øê†NgUª|_‹û,ûû&ûÍ4ìÀÀ¤»¹ŠûNT|~A„{ä÷ëk„~t~sr…s>W×÷÷	ÁÙÜÍªkFüûXvù7w÷$ğçğ8ßğ÷Uù§t¢pottop¢t§¦¢¢¦èŒıø^†XwXyWy|©Œ‹“¦”{_ü!€jg}‚—€³i†wwwywk²tÂ÷ÆÖ÷"Ó‹ù•ùHàùRŸWw˜eÂûS÷¦÷%÷KÅÕ¤šÌŸû€wÅˆ–†r|ƒ}kdûû`ÆCî~¦‹¢£š‘ÈŸûÁwĞ…¢wãû÷û5û0ûU;)~W†w÷}àVs–Œ¡Œœ˜¤°¸÷÷(êû!«\g‹}àuwƒSŠwd‹²dùîğ°øè÷Bsû
SizûI0°ønÓ˜˜ÕŸû§wÕ‡˜~CüQpC~~A‡wø­œ‹°f÷È³c²÷—±x÷ñ÷†ğ;÷¦€øå÷DÅo½\§ršy’Z™g è¡²¶Ú÷.Çû<û¬wŞˆ˜AüQA~8ˆw÷â¦€÷%ìÒô§ û÷Ì<Yb)Š› -Š÷y§Ã÷È]0¦€ ûÈ*O]ûO|“¬÷÷VŒĞdû5 v÷Í÷Í©ø‹ø©÷ÕÍü‹Iø‹û]Íü‹Iü›v£v÷ó÷Û÷ û÷h÷Tø)©r¤lmrrml¤r©ª¤¤ª°§ü¿h²\jrskl¢w¯p•”‹”•‡Š‰iogVg•xÎ­¸ÈÄûb vøE÷ ¶÷ æ÷ ø2ø}«tŸg‡‹ƒ‚Š†•®§®À¯ŸHh^OQW®dº¬¤£«û{«tŸg‚€‡‹ƒ‚Š…Œ•®§®À¯ŸHi^NQW®dº¬¤£«ûb vøÍö©÷ æ÷ ø%øİ¿h²\jrskl¢w¯•”‹”•‡Š‰iogVh•wÎ­¸ÈÄû{¿h²\jrskl¢w¯•”‹”•Œ†Š‰iogVh•wÎ­¸ÈÄÓ‹ù÷ÏñùRùŸûow¾Œ‚t‡€{û!ûxû)÷t€›…š‹˜¡™‘ÄŸû¬w¯‰™„§iŸt²W¥e÷ûTûM>~€2‰w÷ÆŸ2~–Ø÷U÷'÷wÁß¨¢Â‘ü€÷÷÷Ü÷÷Tø)©r¤mlrrml¤rª©¤¤ªûıªr¤mlrrlm¤rª©¤¤©û™’vù&÷CñøùŸû´wÚ‰™}Cüd\€wq|†‘£„²|›qqutp_²nÆ÷ ÈÓ÷øÓ™™ÚÓ•vù#›ù;àùKùŸû`àxÆ†™‚m}„qmû&üû,÷æmÍ©‹™¤–Êûàw½ˆœ{±6÷‹üºš÷pøÆ¨Õ››ºÓ‹ù÷ñàùeŸXz–ë2û|÷÷Q÷QÇÇ£—ÎŸû˜wÇ‡’ˆtrxs4:tuº¶û@û0÷WàŞ–—Ù‘û¬xÙ…–8ü;8€=…x÷¬=‘€—Ş÷D¥¡õ!Ø>ÀF‹tày‚ˆO‰wûb„óø¹¨÷Mó«èø2ø›æ?Ì .EM9dœt©¥››¤™…˜}š}›‡’•©»ª»ÆºUGb}PuVoIy`€XŠ\•Öš©ÏàÀÍ¢½‹¼ûün¨t¢nnttnn¢t¨¨¢¢¨ûÑû/¤ù”¤ãØ÷Àû/¤1l}™©ù<©™™ªå¤ûhıÆûÑû/¤ù”¤÷=Ø÷Šû/ùÆûhråª™}mı<m}}l1rûÑ÷÷ ÷“ø~ªtŸg‚ˆ‹‚†•Œ­§¯À¯Hi^NRW®dº¬¤£«d‹±øß±”øŞøç÷Dtûhjq%û–øCøöšü¡xû>¤òŸ°¨÷÷qüHüö|øÆû*‚¦ø4§¨äÆ÷rxäß÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü#ıèøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûü vøbwÌ÷rûUßo ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œû³ıĞ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{ûbĞ÷o«÷¯¤ĞFÒÀ÷rGñÃ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—û* vø)ÂŒwÚÜ:ß<÷İBßŞ÷Şùmf{~r~t‘“{t—v–s‘u‹UhiI}¨ª“š§•˜ˆ„™¡€¯y¢…¢‹Á©©Ö ü1ıÒøx›]}›¼÷yè^ÄB[p|IDÛª„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ê»Ã›”¬»£kJûeN}xZˆ{ûb–vŒÄø¤°ã¤÷r6İÄ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıtøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±û* v÷]¼‹øˆøˆ÷]¼üˆZûb–vŒÄø¤°ãY÷rİÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•ütøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±d‹±e÷Èµb´÷“²xîğ¬÷r”¢¬¢÷ ÷i ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü[ığªÀøè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥VÀwÕ‡˜~CüQC~~A‡wø¯Ó‹÷[´ø4wšùGü€÷r÷W÷i÷…øû'÷)|š}’|‹z}}zz”}÷.*ü ıdğùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§ûbĞ÷o«÷¯¤ĞFÒv÷r‘ñÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•üòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—ûbĞ÷o«÷¯÷jw¤ĞFÒt÷Ê;ñÉ÷Õøû÷:Kûû:¬÷ò÷$ûòüéø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½åû÷-ûcÙš®¯ÇÆ¥m7—u¡øW–÷\š’‹÷š”ü}¦
ß
_÷ù
endstream
endobj
11 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L/M/N/O/P 82/R/S/T/U/V 238/Oacute 251/ring]/Type/Encoding>>
endobj
13 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 12 0 R/FontName/OHABFE+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
12 0 obj
<</Length 3393/Length1 3393/Subtype/Type1C>>stream
  OHABFE+Times-Bold   @ø øøøøû<ûnúzú:
 ‹‹
 ‹‹   ù   õ  <°   }‡Œ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku                „ 0 # + & 5 * 7 4  3 6 . /  % - $ " 1 » ' "   Y …JŠúQ¯€Í\á.£ğ(|ı4¨€ßâ	F		ò
S
½1˜û+‹÷øM÷÷½÷øq÷hrEo|‚(û*÷3÷.ŞÛ«Ç‹Ö÷@×û*DIûY¦Ä¥¶«¿Ğ¼V@YwSaN^K]Uûûsø3û+ vø¯÷œø^øoù8ü3`ûr¤Ëœ£ Ã÷bûZü¯êû+~ªù§§÷û÷÷9÷û÷
Øøj÷MãbÇûÒÔâ£¼½ÌãAÃû
û 6HûA³UïPè"l]X5&áH÷÷çÚ÷Ôû÷ôa‚gjeR¨CÄÒ¶±±·Â­]?è…ü+Gi_XOeÁàÅ•ª³Æ÷C£kDû+‹¤ù+w÷O÷&øN¤1x›×øÍzûûq Ä™™¤—u\ü:wz(Šrü$šv£v²÷Là÷sµÍ`ºO[jj[[©k·à’’‹“—“‚}fkd>S–tÉ°¢¦©¬± ¾»û+}÷(û(½øÏÛ÷­÷&@÷¨øf÷‹ÜbÇ:¯°Ë±©ÇŞM¿(&@Y$U ®Ç°¤À‹Ç²bMIig,mxè÷ `ÇP+EdZT¨Dqí‹7iprlSÇgé÷9÷÷÷&û+ v÷#÷øEw÷÷&û$÷$èøm÷#÷MøE;dYk_xrûû4‘#û2ûğ÷Šû#÷&÷#èû$÷ûcğ÷a÷»èû+ƒÇO÷(÷S÷Ü÷ø	Ø¸øiù8ûÕ+ûí÷
ºƒ»uÎm´VTU^\XøDZã‹BgqrhVÈhå÷4÷	ğ÷ÜfÍH³V«e“û”¡Ü÷©û+~¦÷ş¹÷„¥§øRøn÷p÷AŞû kx‡}e³÷*ÑĞ÷/²¥û¨jû8û/ûwûBæû÷"÷æî÷û-KûnZuy–¡€|¦‚Úåµ¨‘º’Œ “Ì¢Qû6û+~¥÷„¹÷ı¦¥øRølø&÷>.÷ûû1*ûûÕ9ö°£™¨]û0DDû(kq÷¤÷C÷8÷vû1¦hŠoƒS†s…xMtÅ÷5÷—¨»¡x•›o–62û+~§ù§£øVøn÷ß÷b,÷*ûû,û+ûaûZëû&÷÷ë÷&÷Zû2û û'wN\\wÈ÷'÷y÷&ŸÈººŸNû&ûÒ vø£»÷»Ç»÷º÷£ùÆ]ºPQ[[QQ»[ÅÆ¹ºÆ\kqqkkq¥««¥¥««¥qk÷x¬ù¬®ùVùy÷ã÷dû'÷(ûbûbû'û(ûdûb÷(û(÷a÷a÷(÷(÷bûEŒûhOûûû	P÷÷h÷_Ë÷÷÷Ìûû_›‹¤r«÷Ê¡÷®©r¤ò÷3÷L÷?®øı÷NåHÊû£÷°²°Øò/Äû;ûÇrÎˆŸzXüyX@‚r÷Õ÷?÷Ó÷şû[÷Ùû lpûˆ÷t®š™±Ñ¬`/§ûİ&cZ8`y¶÷©ô¼Xûû+,¬ù]¤÷"İ÷5øpù¤ûórÜ‰ }UüÀMyr_qv˜£¦”‹«²i®ddmj`DÕSê÷#ÔÔ÷&øHÔ››Ó›‹ªl¤÷Ä¬÷­¬r¤ò÷5÷6¥÷¤·ù÷dpûQBZûKw˜µ÷‡÷
„©n™û¥÷çqzûknûˆ÷}´—’Ï÷#Ä`û ¤÷\üÒÿrĞ…|YüwW~€A‚røÛ›‹¤øÿ«¬¦÷U÷6÷T¦ùøoˆ÷]üê‡û]¨¡÷±­÷”ü£B€6„r÷ø¤7}˜Õø£÷€¾oûûš‹¤ù¤÷÷4ø¤Btœ½øxÀ¢ÔŒ¤ûñrÒ‰¡zVüxZuzD‡rÒvù2¤›ù?ùOù¤ûhr«ˆÁŒa{ˆz]ûûÜû÷ĞpÌˆ”‹›§˜‘Ô¤ûãr½‚—¡X÷”üì¦÷vøß£É—–Á•,x­vù:«®¨w÷÷…÷
ìø”÷SÙaÑG­û'Ö9µw ‹¼È¶²ÊçÑIû­§÷mmoƒ……xgg­1û7<û1¼O÷PÍlç_ r‹THY_?ô$BØ÷onûŒ¨ì¢”•›­±ií÷(ïà÷ûÒ“vøywİ÷<÷ø¹f±]\ee]\±eº¹°±ºûÑºf±]\ee\]±eº¹°±¹Ò‹¤øş¬r¤÷÷5÷K÷>øù]¤t‚‚˜û]÷²÷°¶¹ß÷
,ÈûOûÓrÔ‡™{DüNBƒ‚<€r÷å¤@•}šĞ÷V¥÷cûÍYøˆûdjû$Š÷”ø«š•ºŞ±^)Òx¼ù¤í÷2÷Õ·ùOù¤ûprÛƒyBûÄû*TGû(]É÷÷áÖœ›ÛŒ¤ûårÍ†›yFûá/\¿`a¼Ïvà×Û©¶²¯³ŸÏá÷ÓÆ™›Ë”÷¸‹¤ù¤s£óµø¦÷.øú+¤<•–ÒøOÓ™šÔ£ûû[ülû\ølûørÕƒ™WüpO€‚<€r÷~¤7“yÔøf÷üâ¦÷øñüS}@„rÒv¤ù¤ò¶øB·øùNù¤ûkrÕ„vDûÃ‰ûîø?ûfr£‡™ºSüoT|}Cr÷v¤>•xŸÏø%øøQü²¦øáÄ˜™Ì”ü$Ò‹¤r®øó­r¤ë÷6÷•÷AÜùD÷ë÷eû÷û}ûÃrÌ…œ}\ü^vzN‡r÷Î÷p÷ ÷÷füûA{ûVH)ûa|š¶øŠ°˜•»÷Òûû]›‹ªl¤ù¤ó÷6ğù÷xnû*KO\ûDx—¸ølØ™—â¤ûğrÎ‡|XüyğX‚ƒ?røÕÒyºù	­‡w¼÷EûEù`¤ôùA÷m¤;4Ig;‹ûIñ÷a÷kÈö÷çÛEûÇ¤ô÷~pk~}yèoB½‹#ûVû)û0û`ûd÷%û"÷j÷Î®÷îÒ‹¤÷@²øZw”ù9ùB£]—W÷ûsø¢nûpü¸e.‚Yr÷_¤Ot—¤š˜±«Ù÷s§QRt~ƒ|ˆ€ˆ‹Y†r÷€ûVè÷‡c‹¤÷ª®÷Ä­r¤î÷5÷:÷?Üøéø÷0Ëû>ûÓrÎ„š{GüN=z‡I€r÷á¤>”—Ó÷M°öÂ–¦»Å­«ÁËû?ˆûgjû÷ ü¥›•±Ù­]!÷xvù„v®ùVùy÷ãûbû(û(ûaûaû(÷(÷b÷d÷'÷(÷b÷b÷'û(ûdûEŒ÷_J÷ûûKûû_ûhÆû÷	÷Ç÷÷hzø±v~mxû#4T÷÷0›•Ÿ‹¤Ÿwsc‹¤÷Ä¬÷­¬r¤ò÷5÷.¤÷£ŞøÙøo÷]üÉrĞ‡}WüzY}Cƒr÷û¤2u™À÷~õˆ¬i™û	¤÷ærxû	jk&‰÷~ş²—“Ç÷#Æ\ûxøa—÷_›÷p”÷Ÿ“üu¤
¤Œ
_÷ù
endstream
endobj
15 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
17 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 16 0 R/FontName/CLWRCQ+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
16 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  CLWRCQ+ZapfDingbatsITC   6‹û¹Ïƒ
 ˆ?‹‹
 ˆ?‹‹   h   e   k‘   ¬ a73    ‡ %<ø
ú0û¹ÉıÌù7ùÌıYVøçúüçäú!ÑúsúsøÍù
endstream
endobj
19 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero 50/two 52/four 56/eight 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
21 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 20 0 R/FontName/AOGMZT+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
20 0 obj
<</Length 3450/Length1 3450/Subtype/Type1C>>stream
  AOGMZT+Times-Italic   Cø øøøø€û=ûmú…ú
 ‹‹
 ‹‹      ü  ;¬  Y }‰002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    ' C V  7  X     Y ìLO³E¿|Á>³Ş+Ÿ ­ZŞ	W	¼
L
z
Ï¾Ş- vøÿ®ÆøÑùù"ü§aû.‡¡ºœ¤¥Ÿ¤¬¦‘÷û#ü¥}YszF„{÷¶›9‘‚«•‘¥’¥÷ ø‡ÁÖ¨rKŠ‚‰xœŠû*—v©vøOvø]ğøpô—_Qvwz‹ƒ„’•–‘™“Ä÷e•®‘©‹˜²p§fKFMû#-‰÷
øK…L}w†Bƒz¤ŒœŒ¤‰‹tuj|Pûü‹Ö±÷)›µ²ÆÁÜÍÆ®‹›‹—€‹}‹†Œ‹ƒnWûS}W‚ağpœ{§¾·®Ú»ûb¸ø¢ªá÷yÌø/ø
¸o¢Tûû2û9û&3¾VàÎÕ²ÏÉ—CQk{`‹Se°Á™Ÿ’¥¨÷, ò×‹âJ’7+Gûv·°æÏÔÀ Œš{tü$d v÷v¯ø+vXøûøÈ›Sƒ•Ó,øÌqûµü‰Aû}{bƒ{÷O›\~’¢˜“¥—¢Å÷÷pŸûŒŒ‚‹gx~PŠ{¾÷šûV÷(÷˜û*—v©vøNv™ø`ğønó|˜UFy‹‚…’”’ •±·÷4—·”´‹š°q¤e,4û&H^‰Ë÷e‡ût‘Œ[‚{¾‰˜†x~‚n…v‹ƒl@û§Ö´÷$¢Ã¼ÑÊã±¬¯‹˜‹•‹z‹€…lf`û7{PŠƒ|ğl›{«¹©¤ãËû*€¼[»ø¡œŞğøpï–~~YSy‹„†“•¦–µØ÷Æ…L„€[ŠŒ€®od‹ûû1ûJû-=®bÎÑ²©÷ãˆ{L†q‹wğo˜¨±¬¥ßÍû÷”3,ûz!dr§·åé÷q÷®¢qdü•v´÷‚÷«ù;†Q{ˆ9{¤·Šr„–v>"üv;ˆ}‹zi›yªÁ§¢ñÑ”UCwxu‹†‘•’š“©û™“v¢vøA£Œv÷ Ô¹Ø|øøO}}‚„‡~|nqœ‹cC[aJ-÷?‹@[nkaRl³ìz|üwû4š›’‘–|­ªx‹±ßÉÂÖêûÙ‹Ô¬¢Ÿ­½«g=•|›û*•vøYv¦ß÷¦Şøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPüûMvøï«÷x¡¯êø:øú±g¦Xaexdjibu\j#0ƒkå3ü9tûlX_‹„‘•””‹™ zšsw}zsi¬q·åĞì÷MµÔ÷Õ÷ ‘« ÷0¦±ÓÂ™•†„Š†€‹|sš{¡¢¡d v÷Å°÷®©ø‰òøğøŠîBÀûûŒz«†±`}‡v`û
ü={R„…P€{÷‰›S’“§š—”­À÷U¶…¤‰±‹÷,óÛ÷	$‘ûOWûxt{Ñ÷‹‘ —“¨‹æ´g;û™ v÷èñŒv¸øğø0øªxŸnX@7(^‚wŠ¼÷[ğˆWW‚W‚{“Œ“ ˜y~…ih:û¹×¶÷ š´®Ğ°ÕµÀ ‹ğ f‹¶¨œ«Ó—v©vø¿\º—ùFxùRô}—ZOxyzŠƒ†•”Œ’£Ä÷g”­‘©‹˜¯s§k24ûHa‰¦ã•±‹œ¯t£iO?Dû8ˆÄ÷[ˆ$vŒŒP€{ÀŠ–‡zƒ‘{M8ûÊÖªğŸßÉãxÑ¼Â»¨˜“‚|ƒŒ|T‹‰;ûº×²÷, Â»ÏºÏÁ»¦‹—‹”‚‹}‹†Œ€^ZûZ}Q‡z~øoš{¦¹º°ØÀûb€¯ø5w©àø<÷ü½a«Hû%û û'û.)¿UëÔÉ®ÔÀ{”cZSk[‹Sh¸Ò÷$ì÷ñ£šƒ{|‚‹ru›|£¦¥ü–vø+¬¯÷˜÷¼øB;§òŒ‹‹ˆ……ŠŠ€‚\Sbib{m€‡ˆ‹‹‚‹”‹‚ÖBû§t5Œ‹‚uŠ y¦¤£–Ÿ¢›˜œ³Ä~‘rlpj{}‹…‘–Œ›ß÷Òßû*ûMv÷Wø¶øåøi÷Éßa¼BL[l=T‰§î‡’û0uz©­ˆ‹p„†s‚jûüN~Y……[†|÷bš\y”¡©¨ğ“®}¦˜ˆ¨÷!÷0÷=÷+1“û(û û5'ltš¡¹»÷(¹Ì¤Ä¼¿³¡mWûbûLvùv÷àéc³Ğø>ø²u£hàv{|wĞZÁ—‹dP,û/p]w÷…¬N÷qy‹vE}VzŸ“Œ”Á¤Yûl¼šG•V~{„|tmxqplww€…‚‹w‹}¨p‹t‹z{‹u‹pŸyª‹°‹¼²Ğà÷	÷#÷÷ƒ‹Úû*‹Öø¥ÔøàøWøíFÔ-*?Q%gŸ„²Íµ§É‹ÒÀWDP`C%ûûeûtz÷÷½÷z’rXv~U‹ûR÷U÷U÷
÷
©º‹Ïû*„§ù§«Ú÷ÈÙø…øH÷*Oæ(û.û,û|û~ûÎ0ê÷1÷&÷j÷y=âû*Tû]J5_jjvhUj½Ü÷½÷UÁîÆ¬·­·¿ª\<û*„¡ù¢©Ï³Ù÷-ÖxÏôøø«ßCÅ%ûCO0F¹\´ZûfA@4(İE÷
ø÷çØòÎfÎ=×ô÷­À¼ĞGJto0^NÈiªÃÉµ·ÇÊ·\FøSü<RO@9RÄŞàºÇñ¸w›z‹Õ;™vVd v÷Û®÷—¬“ùùù"ü†{Ï…•†n}†p…tûüO{Rƒ„R€{÷›Qy–¨–Œ“©É÷sÅŠÁŠ¹‹Yx‰|…sœ…×÷x‘Z,“ûBˆÌ÷}‘¢•Í‹÷,ª~M}‹‚‰xŸ‰û*¡ø¼øàøn÷ÔÔ[¼D2V:J^Šğø†U‚‹#|{ ‰¸‘nyf‡{ûüŠˆrÕnÉ÷)÷:÷B÷06~#ûûSûh|—¦ìë÷‰÷µ§iWû*€ÀmvøNvªv÷à÷¸øo÷ }”[Nyy|‹„…‘•—Œ˜¼‹ Ù÷¼AaûrT`HP/XUn‹q‹¥“æø ¸ˆQ}zˆ@€} ‰²’lƒ‹Š‚gYûW\†p‹zgx¯Ğ¾¾÷O÷hûƒhwølœy©Ï¯Ğ»®ü$‡÷÷¬³s§invxpz’{š}ƒrurVg•xà¼¶Á‹Ædvù4v×øøùDù›ûN{¿„–…uy|hfKû^ûó‡IøJŠ‘‹‘‹«š”É’›û…{À„‘ƒ™9çüÃøøı›¦™•¥û* v÷EÍKËŒøq°ørù:cü5üCwG÷™ZûGÚğº÷EîšÍ,™÷×,û×ûi÷Å÷Õœvø`v¡v÷Õ÷:Ê÷H»üùø¬v jt}|xj¶†‹f]_Iûû&k÷ı‹‡†‹‡‰Šƒ†ûSûÄ‰…çƒæzåü¯„‰ƒü‰ˆ‹Šˆ[z‡V‚}¡Œ‹‹§Œ“…“t•mšû‘#4€ŒŠf™“‘”·¤÷:÷º¨ûĞq…’Œ‘“’¢ÉÖ÷=÷]ïü$€÷¦÷÷·ªr¤mlrrlm¤rª©¤¤©xøA™÷g¢’‹÷¡üs¡
¢
_÷ù
endstream
endobj
51 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 65/A 68/D 70/F/G 73/I 77/M 80/P/Q 83/S/T 87/W 97/a 99/c/d/e 103/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v/w 121/y]/Type/Encoding>>
endobj
53 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 52 0 R/FontName/HBYZVQ+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
52 0 obj
<</Length 3935/Length1 3935/Subtype/Type1C>>stream
  HBYZVQ+Times-BoldItalic   Cø øøøø€û\ûlútú-
 ‹‹
 ‹‹  	    J¯  ; }“002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    "  ' J T I F S B O E . 8 % W 1 P M H 2 5 * U  4 Z D Q V N X ( !   _ b âOÅ>¡ókÜgñuãB¼M¡ó	?	Œ	±
+
©
öw·-«œ‹¤÷L²øHwø÷ ø/ù@süüàm\x{hƒr÷Y¤Zz“¤–‘”›Çò÷j‹š7‹_d|€K…r÷Ã¤K„“~Õû\ø±û‰ûMü$œ‹¤÷Í¬÷«s£~ù3Øù&ù1ü§sÍ‚’‡r|‡s…uûüU~[|}Wr÷»¤T{”¨šŒ™ÀÀ÷]õŠ©x‹GŠˆu§†Õ÷¥o\0s}û‹{Ç÷rø¯•–“·È½~s§¦s”pK¥…ü—vøÃ÷÷÷÷Vù@fmmff©m°°©©°°m©f¨ûr/z…Š#q¹Š—…r†‰„‡{Sûl€b‡v‹|e¦q´ÇÃ¸å¿u™jWqox‹ƒ„’“”Š‹”®‹È÷zª÷û™“vŒ¨ø1«Šw¹ë´ê\÷ßøao{ƒ…†}|nv¡‹^:VZ?T™nÎ=³[›mrlrsjYjºá~qüuû:¥™““‘™|¡¤x‹·äÈÂÙõûÜ‹Ò§Ÿ¢«¸©c<˜\¦ˆ-—v©vøbw÷ô÷p÷¹ùO.zn‡6‚q£²h‰}…vû.üË÷¦ì§İ¡¸¸èÊÓ¯‹™‹”…‹{‹a3ûS‹8ğh¦r°á´ÔÉµv›eSrp}‹ƒ„’“å÷‹È¸n¨^GT^û4‰Œûb~Ë÷«÷l¬÷#û#÷÷>çô÷(÷j÷«¾àº”u(AM8v÷<CLegocì^u§ÁœŒ”¢å”÷:Î÷½`¯Oû'û"û<û13ÊLâÙÂ³íÄû™ v÷×÷ vø-÷wøcQ|‰‹û ~p¶Š–†w}V~]>û¡÷½÷2©ëÊö¥‹œ“e‹®®£©·´u¤h\`XûJ†û*’vÑ÷ÿµv÷p÷ø9¢Š™xnIHûŒ1rx¢ªÌÜ÷Ş†÷P¯û…yS‰·…s£bûû)ûRû3=µ[ÎÇ·­çÃŒ€b‰ƒ‹}ğd§p³¸½¶ŞÁvšfWxx|‹ƒ†‘•§‘¨§ç-—v©vøbw÷wp÷…øaS~Y„.…p «Œoqj Š†‹ƒlPûh÷÷èâğ½¥˜–‚~i4û[‹:ğb£u¸Ä¼´å¾u˜eP}{zŠƒ„’•¤ã÷i‹Ö½p¢X6N/*J‰û*ÓDÒ÷ıµv÷p÷¢ø9¢šwkbDû /rz£®ÍÛ÷€â÷Š÷«FyW†4…p §˜‚w„‡z…ueût£w”p‹û
û/ûSû1ğB¸UÇÌ¹¯æÀ‚cŠ‚{pd¡u±¼¼µß½u›mZwu{Š…Š†‘“¢º÷:”¬÷ƒ”v—¤øÿ¤núEğùAø½ûü\}Vu|K‡r÷Ì¤R|”«— ‘¡÷øV™¿œš½¤ûiûÇüpŠTøpûrr§¸’b~‡s…vûü	fûƒ~T|r÷c¤N‘wš²—œÊïø ŒğÍü¿§øøÌ÷ƒvù*¤ÌùÿøÎy÷³øã¤¿œ™´¤ûOr¾‰—„m{ˆrû.ûÙ‰j÷¹ˆ¦ˆ©‹™±“’Á‘¤û rÃ†šwEû(ûÈŠc÷îŠ‘‹‘‹‘®š—¸¤û¨rÊ„…•EÚü×¨÷yø{ŒÇü{Ó‹­øñ©r¤ø¬÷'ğçù1rÏƒ‘„o€‰…{Pûü?}X{|Y„r÷²÷•÷N÷9÷x÷DûïûTğIG§’›•®÷ÀNûûfûWCBWBf5ay–£ŒŒ˜‹‹—·ûb“vøpwã÷Ş÷BÔè÷~÷^÷Uã÷æ±pªiğnqqlè_¶~‹ijbN6.ˆ÷V…ÃvàW}r‡=€q›ŸŒ{•šr˜0‰!‹‹‰û‰Md‹¤÷¹®÷±ªs£øe÷&è÷àøå±•“’¬¾ªiRWyMrhmud|S€„‹x‚k‡²œŠ¤÷7÷ Ù÷
òD¿û"û²øsÏ‚‘ˆo~‡u…tûüV}YUr÷º¤Q~“©—¢‘¡û*}©ø5¨ˆ÷÷`÷÷¯øbû'ûû3û;5ÏKç÷%÷÷0÷9èLÉ.ƒn©ŠšvaBSû¬+iy¡·Ö¿÷­ö†ü—v÷³÷µùP3ym‡1‚q¢³jw}\„q'ûÿ}W„j‹zb¤sµÜ¼ÖÇ²ušiUqqy‹‚…’•—’¬šÀû*û_­÷Kv÷4«÷‹ªWâ‹÷÷÷ @÷	ö÷„Øo‚¥~šwt`_qEC^©»·È³›õ÷!øK¨œtcWiûEn|Ÿ±¾¬÷ĞúûCü>+uipSN×`÷ ÷&ëÇæÇg¬ûªVši•y™‹››œ˜š™ƒ‹ õ÷êÚíœŠ’‡ÎÃû¥ik“aû$9*V¦dÀv9]}}emw´|Óûcãğ­ù¬¦÷%ø
÷$øSù Èˆ±\Cû+üûCJeºÛ÷íø÷E‚ü7ıÄ™sºŸ­“«‹ŞÏ\‹èô×¶óÕvŸ\U[rO‹q{˜bb˜k•vbN’“ˆ˜˜«ªŠ˜”‹‘÷_÷c÷÷}÷&íû!ûkûbûyûƒ ¾>ëh¨€Œ‹ˆ‰uxd‹¤øõ®i­½øëğùù1üºeû?¤„¹ìÉ´÷‘û'ü¯|UrzI‹r÷ß¤C€‘ª˜¨‘ ğ÷øî†ªh“û¦‰û™‹£ù ¤køH÷›£S|”§™‹“™À‹’¢÷ø.™¾ º¤û½rÌ„”†r~†q†xûüW}X{|Z„r÷»ü—vø4¶€÷·÷‹øçhZ>^f2dh¾Lûp‚mxF‹n`¥r¸Å»³ëÆu™gStsy‹ƒ„’“š“¯œÈÈ÷oŞ¶Cü$Åà\ûI÷¹ÙæŞÃh³Ybnl`MÑ‹beZ[Fl-y­ù®‡wğ÷÷÷ø÷Åø@G¿}Ÿ·Í±³ËÜµYû•¦‡ø³÷\ny„uø]l¨‹Aû26!û?÷‰_‹û!FVVC!^áñˆmŒhûs©§—’’¯·hæ÷äÛ÷ŞiÈûíûbûaÜ:÷ø»w wô÷·÷KËª˜ø0µ–‰ûT²¥û•JjWQIjêqm®‹gntsli¦p°ãäã÷Eõâ÷&¾÷Í½imìnqpkúVÂ‹b]Iûyg‰~Ôw÷wärÙK|vˆJ„ûb~Ìø¬†÷÷)÷÷Ñ÷!GYov`_n¯ÄÏÄ÷må™”„‚}vz‹pm¤tª²£¦¶Â^®Eûû%û:û//ÉLç×¼­ñÒû*û`¥÷:®øÓ÷Ô÷÷køc*{£û|p¹Š“‡w„nƒjûü>~X}€_Šq÷Œ¥XŒ}’¥§¥Ù•º{«›†¡÷÷"÷J÷<ÙbºIZ\p;R‰ïª£™xlADûˆ*uz› ¬´÷™´Û§º¸²-—vø_w«wšøpĞø{øVû
aû&wUgGfFZXn‹}‹ƒ”‹›‹–¡•¬ğé÷ÉEI|B‰p»‡“‡u}†s€f_û+‚k…j‹xV£sÀÂ³¦ØÃ“–‘ª¶‰{\…opc¡w·ÄÅºÜ·v˜fUxx|‹‡‘˜Ğ™“¯š¾÷—v©vøÔŠwøÚ÷h÷}øaO~~‰ûq·Š•†w„Œ„kû‹ƒkMûq÷÷÷æ÷­––’‚|‚‰~†|‹Gûoiû÷°÷µ÷á÷¹‹™•~b3ûO‹8è_¢v¹Ç´­ìÃu—eQ|z|‹‚„’“°ã÷L‹çºm¨YXL`û?œ¸¡¨ø´q¤b-DûH]ˆœ“vøow w÷Âï÷ÖØ÷é~ÖÛ÷X÷e÷±r¦hmqolc´w‹ineQ:/øl÷áoû-û¥‰Øˆ÷‚×vÑW‚X‚Wq°Š‘ˆ“v£M“ûF‰D‰6¦Äá´É­Ğ¯ÌŒ¢û®Óy±÷±¤÷Ô¯ ù?ù:ùBnt€~„zl`©4û5kG>*6Rûûû5÷û÷GÒ÷  ¤½§™»÷HÒ‘Á‘¤û²r‰˜–Š‘­‡•‚rp_û?}{y{f_(NÑ÷÷/è÷º÷Så¸Pû¨†xøV˜÷b›š‹÷œ–üv¤
ÚŒ
_÷ù
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
88 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
89 0 obj
<</OP false/OPM 0/op false>>
endobj
90 0 obj
<</A 91 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
91 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
82 0 obj
[92 0 R]
endobj
83 0 obj
<</Length 14577>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 60 730.8196 Tm
(diac channelopathy could not be excluded. A silent muta-)Tj
-0.008 Tc 0.008 Tw 0 -1.23333 TD
[(tion may predispose to QT)70 (c interval prolongation, which)]TJ
-0.02499 Tc 0.015 Tw T*
(manifests only after exposure to a specific drug and/or oth-)Tj
-0.015 Tc 0 -1.23334 TD
(er risk factors.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 0 Tw 6 0 0 6 118.1886 695.2697 Tm
(22)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 126.6384 691.9697 Tm
(Increased vagal tone due to the increased)Tj
-0.017 Tc 0.01601 Tw -6.34651 -1.23333 Td
(amount of acetylcholine in the synapses is the most likely)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23333 TD
[(explanation for QT)70 (c interval prolongation and arrhythmias)]TJ
-0.036 Tc 0.021 Tw T*
[(w)-15 (i)-15 (t)-15 (h)-15 ( )-15 (A)-15 (C)-15 (h)-15 (Is. In a canine model, vagal nerve stimulation pro-)]TJ
-0.03999 Tc 0 -1.23334 TD
(longed the QT interval by 1 msec for each 0.82 msec prolon-)Tj
-0.037 Tc T*
[(gation of ef)20 (fective refractory period.)]TJ
ET
BT
/T1_1 1 Tf
-0.03439 Tc 0 Tw 6 0 0 6 199.1725 630.5197 Tm
(23)Tj
ET
BT
/T1_0 1 Tf
-0.037 Tc 0.021 Tw 10.5 0 0 10.5 207.2026 627.2196 Tm
(Data from studies per-)Tj
-0.026 Tc 0.011 Tw -14.0193 -1.23333 Td
[(f)1 (o)1 (r)-24 (med by phar)-25 (maceutical companies did not show statisti-)]TJ
-0.015 Tc 0.381 Tw 0 -1.23333 TD
[(cally significant dif)20 (ference between galantamine- \(or)]TJ
-0.017 Tc 0.002 Tw T*
(rivastigmine-\) and placebo-treated patients with respect to)Tj
-0.03799 Tc 0.02299 Tw 0 -1.23334 TD
[(QT)70 (c, PR, RR, and QRS intervals.)]TJ
ET
BT
/T1_1 1 Tf
-0.036 Tc 0 Tw 6 0 0 6 189.0848 578.7198 Tm
(24)Tj
ET
BT
/T1_0 1 Tf
-0.03799 Tc 0.02299 Tw 10.5 0 0 10.5 197.1018 575.4197 Tm
(Our observation and oth-)Tj
-0.015 Tc 0.071 Tw -13.05731 -1.23333 Td
(er case reports are therefore important for postmarketing)Tj
-0.02 Tc 0.005 Tw 0 -1.23333 TD
[(safety surveillance. The full spectrum of adverse ef)20 (fects of)]TJ
-0.03 Tc 0.015 Tw T*
[(AChIs manifests only when a lar)20 (ge number of patients with)]TJ
-0.019 Tc 0.004 Tw T*
[(dif)20 (ferent comorbidities not present in the original trials are)]TJ
-0.01801 Tc 0.002 Tw 0 -1.23334 TD
(treated. The Naranjo probability scale indicates that in our)Tj
-0.03101 Tc 0.01601 Tw 0 -1.23333 TD
(patient, galantamine was the probable cause of QT)Tj
-0.0309 Tc 18.79954 0.00001 Td
(c)Tj
-0.03101 Tc 0 Tw 0.64792 0 Td
(interval)Tj
-0.032 Tc 0.017 Tw -19.44747 -1.23334 Td
(prolongation, syncope, and delirium because these reactions)Tj
-0.015 Tc 0.08099 Tw T*
(have been previously reported, the events appeared after)Tj
-0.03799 Tc 0.02299 Tw T*
(galantamine was readministered and improved after removal)Tj
-0.036 Tc 0.021 Tw T*
[(of the drug, no alter)-28.9 (native causes were identified, and the re)]TJ
0 Tc 21.95292 0 Td
(-)Tj
-0.03999 Tc 0.013 Tw -21.95292 -1.23334 Td
[(actions were confir)-21.6 (med by objective evidence.)]TJ
ET
BT
/T1_1 1 Tf
-0.03799 Tc 0 Tw 6 0 0 6 237.3361 436.2698 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 70.5 420.0198 Tm
(Spontaneously reported adverse drug events are impor)Tj
0 Tc 20.95294 0 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95294 -1.23334 Td
(tant means of postmarketing surveillance, especially when)Tj
-0.008 Tc 0.008 Tw T*
(the events are rare. Analysis of the ADRAC database re)Tj
0 Tc 21.95293 0 Td
(-)Tj
-0.013 Tc 0.013 Tw -21.95293 -1.23333 Td
(vealed that, in addition to well-known gastrointestinal ef-)Tj
-0.006 Tc 0.005 Tw T*
(fects, use of AChIs carries the risk of delirium, syncope,)Tj
-0.02499 Tc T*
(arrhythmias, other cardiovascular disturbances, and sudden)Tj
0.011 Tw T*
[(death. Clearly)65 (, the reporting rates are not synonymous with)]TJ
0 Tc 0.09 Tw T*
[(incidence rates. Despite obvious limitations of sponta)2.1 (-)]TJ
0.037 Tw 0 -1.23334 TD
(neous adverse event reporting \(underreporting, missing)Tj
-0.00101 Tc 0.00101 Tw 0 -1.23333 TD
[(clinical infor)-25 (mation, failure to identify comorbid condi-)]TJ
0 Tc 0.129 Tw T*
[(tions\), this infor)-25 (mation should not be ignored. Galan-)]TJ
-0.006 Tc 0.006 Tw T*
(tamine had the highest rates of reported arrhythmias and)Tj
0 Tc 0.054 Tw 0 -1.23334 TD
(sudden death in comparison with 2 other AChIs, while)Tj
0.03 Tw 0 -1.23333 TD
(rivastigmine demonstrated the highest rates of delirium)Tj
0.021 Tw 0 -1.23334 TD
(and syncope. As the total number of reports for each of)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23333 TD
(these 2 newer drugs is about 2 times higher than the rates)Tj
-0.02499 Tc 0.013 Tw T*
(for donepezil, some reporting bias could not be excluded. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 60 184.8198 Tm
(Conclusions)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 70.5 163.8198 Tm
(Our case, along with previously published reports and)Tj
-0.02499 Tc -1 -1.2381 Td
(cases identified from the ADRAC database, illustrates that,)Tj
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(in addition to gastrointestinal adverse symptoms, AChIs)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
[(may lead to delirium, syncope, and prolongation of QT)70 (c)]TJ
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(interval, thereby increasing the risk of life-threatening ar-)Tj
-0.024 Tc 0.024 Tw T*
[(rhythmias. Such adverse ef)20 (fects may appear simultaneous-)]TJ
-0.02499 Tc 0.002 Tw 0 -1.23809 TD
(ly after galantamine readministration, as in our patient. Ad)Tj
0 Tc 21.95296 0.00001 Td
(-)Tj
-0.00301 Tc -21.95296 -1.2381 Td
(ministering, discontinuing, and restarting AChIs require)Tj
-0.007 Tc 0.007 Tw 0 -1.2381 TD
(vigilance and careful assessment of risk factors that may)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(precipitate such events.)Tj
ET
BT
/T1_2 1 Tf
-0.01801 Tc -0.00999 Tw 8.5 0 0 8.5 318 731.8055 Tm
(Alexander A Fisher)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 394.5556 731.8055 Tm
(MD FRACP PhD Doc Med Sci, Associate Pro-)Tj
0.008 Tc 0.005 Tw -9.56945 -1.125 Td
[(fessor)55 (, Australian National University Medical School; Consultant)]TJ
0 Tc -0.028 Tw 0 -1.125 TD
(Geriatrician, Department of Geriatric Medicine, The Canberra Hos-)Tj
-0.01401 Tw T*
[(pital, W)18 (oden, Australia)]TJ
ET
BT
/T1_2 1 Tf
-0.005 Tc -0.02299 Tw 8.5 0 0 8.5 318 693.8055 Tm
(Michael W Davis)Tj
ET
BT
/T1_3 1 Tf
8 0 0 8 385.5823 693.8055 Tm
[(MBBS FRACP)129 (, Associate Professor)55 (, Consultant)]TJ
0 Tc -0.028 Tw -8.44779 -1.125 Td
(Geriatrician, Department of Geriatric Medicine, The Canberra Hos-)Tj
-0.01401 Tw T*
(pital, and Australian National University Medical School)Tj
ET
BT
/T1_2 1 Tf
-0.01601 Tc 0 Tw 8.5 0 0 8.5 318 664.8055 Tm
(Reprints:)Tj
ET
BT
/T1_3 1 Tf
-0.011 Tw 8 0 0 8 356.0462 664.8055 Tm
[(D)1 (r)56 (. Fisher)54 (, PO BOX 1)74 (1, Department of Geriatric Medicine,)]TJ
-0.009 Tc -0.01801 Tw -4.75577 -1.125 Td
[(The Canberra Hospital, W)18 (oden, ACT 2606, Australia, fax 61-2-6244)]TJ
0 Tc -0.01401 Tw T*
[(4036, alex.fisher@act.gov)74 (.au)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 6.5 0 0 6.5 318 626.8055 Tm
(W)Tj
0.00549 Tc 0.93167 -0.00001 Td
(e)Tj
0.006 Tc 0.008 Tw 0.85332 0 Td
(thank Dr Patrick Parcell for providing ADRAC data and Robyn Muscat-Prest\i)Tj
0 Tc -0.011 Tw -1.785 -1.23077 Td
[(and L)37 (yn Cridland for their excellent secretarial assistance in preparation of\ this ar-)]TJ
0 Tw 0 -1.23077 TD
(ticle.)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 10.5 0 0 10.5 318 582.8055 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.024 Tw 8 0 0 8 322 564.8354 Tm
[(1.)-500 (Birks J. Cholinesterase inhibitors for Alzheimer)-35 (\325)55 (s disease. Cochrane)]TJ
-0.02499 Tc 0.013 Tw 1.1875 -1.24625 Td
(Database Syst Rev 2006:CD005593.)Tj
-0.00101 Tc 0.00101 Tw -1.18889 -1.37125 Td
[(2.)-499 (Farlow MR, Cummings JL. Ef)20 (f)1 (e)1 (c)1 (t)1 (i)1 (v)1 (e)1 ( )1 (p)1 (h)1 (a)1 (r)-24 (macologic management of)]TJ
-0.02499 Tc 0.013 Tw 1.18889 -1.24625 Td
[(Alzheimer)-35 (\325)55 (s disease. Am J Med 2007;120:388)-25 (-97.)]TJ
-0.00999 Tc 0.00999 Tw -1.19729 -1.37125 Td
[(3.)-490 (Arias E, Gallego-Sandin S, V)60 (illarroya M, Garcia AG, Lopez MG. Un-)]TJ
0 Tc 0.01601 Tw 1.19729 -1.24625 Td
[(equal neuroprotection af)20 (forded by the acetylcholinesterase inhibitors)]TJ
-0.03999 Tc 0.007 Tw 0 -1.24625 TD
(galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells:\)Tj
0.013 Tw T*
[(role of nicotinic receptors. J Phar)-25 (macol Exp Ther 2005;315:1346)-25 (-53.)]TJ
-0.022 Tc 0.022 Tw -1.20914 -1.37125 Td
[(4.)-478 (Thompson S, Lanctot KL, Herr)-25 (mann N. The benefits and risks associat-)]TJ
-0.01199 Tc 0.01199 Tw 1.20914 -1.24625 Td
[(ed with cholinesterase inhibitor therapy in Alzheimer)-35 (\325)56 (s disease. Expert)]TJ
-0.02499 Tc 0.013 Tw T*
[(Opin Drug Saf 2004;3:425)-25 (-)-125 (40.)]TJ
-0.017 Tc 0.017 Tw -1.20454 -1.37125 Td
[(5.)-483 (Rowland JP)110 (, Rigby J, Harper AC, Rowland R. Cardiovascular monitor-)]TJ
-0.01199 Tc 0.01199 Tw 1.20454 -1.24625 Td
(ing with acetylcholinesterase inhibitors: a clinical protocol. Adv Psych\)Tj
-0.02499 Tc 0.013 Tw T*
[(T)35 (reat 2007;13:178)-25 (-)-24 (84.)]TJ
-0.019 Tc 0.019 Tw -1.20609 -1.37125 Td
[(6.)-481 (Suleyman T)75 (, T)70 (evfik P)110 (, Abdulkadir G, Ozlem S. Complete atrioventricu-)]TJ
0 Tc 0.02699 Tw 1.20609 -1.24625 Td
(lar block and ventricular tachyarrhythmia associated with donepezil.)Tj
-0.02499 Tc 0 Tw T*
[(Emer)20.8 (g)]TJ
0.013 Tw 2.75769 0 Td
(Med J 2006;23:641)Tj
0 Tc 0 Tw 7.32734 0 Td
[(-2)25 (.)]TJ
0.006 Tw -11.27253 -1.37126 Td
[(7.)-500 (Nelson MW)90 (, Buchanan R)55 (W)90 (. Galantamine-induced QT)70 (c prolongation)]TJ
-0.02499 Tc 0.013 Tw 1.1875 -1.24625 Td
(\(letter\). J Clin Psychiatry 2006;67:166)Tj
0 Tw 14.45751 0 Td
(-7.)Tj
-0.022 Tc 0.022 Tw -15.66714 -1.37125 Td
[(8.)-478 (W)80 (alsh E, Dourish J. Prolo)1 (nged QT interval with rivastigmine \(letter\))-1 (. )1 (B)-1 (r)]TJ
-0.0251 Tc 1.20963 -1.24625 Td
(J)Tj
-0.02499 Tc 0.013 Tw 0.60138 0 Td
(Psychiatry 2002;180:466.)Tj
-0.009 Tc 0 Tw -1.79837 -1.37124 Td
(9.)Tj
-0.00999 Tc 0.009 Tw 1.22155 0 Td
(Luo S, Michler K, Johnston P)Tj
-0.0096 Tc 11.58706 0 Td
(,)Tj
-0.00999 Tc 0.49026 0 Td
(Macfarlane PW)Tj
-0.0096 Tc 6.09764 0 Td
[(.)-250 (A)]TJ
-0.00999 Tc 1.45271 0 Td
(comparison of com)Tj
0 Tc 7.57748 0 Td
(-)Tj
-0.015 Tc 0.015 Tw -27.22971 -1.24627 Td
[(monly used QT correction for)-25 (mulae: the ef)20 (fect of heart rate on the QT)70 (c)]TJ
-0.02499 Tc 0.013 Tw T*
[(of nor)-23.9 (mal ECGs. J Electrocardiol 2004;37\(suppl\):81)]TJ
0 Tw 19.78093 0 Td
(-90.)Tj
0 Tc 0.20799 Tw -21.46844 -1.37126 Td
[(10.)-500 (Mason JW)90 (, Ramseth DJ, Chanter DO, Moon TE, Goodman DB,)]TJ
-0.002 Tc 0.002 Tw 1.6875 -1.24625 Td
(Mendzelevski B. Electrocardiographic reference ranges derived from)Tj
-0.02499 Tc 0.013 Tw T*
[(79,743 ambulatory subjects. J Electrocardiol 2007;40:228)-25 (-)-25 (34.)]TJ
-0.024 Tc 0.024 Tw -1.6875 -1.37125 Td
[(1)35 (1.)-476 (Loy C, Schneider L. Galantamine for Alzheimer)-35 (\325)56 (s disease and mild cog-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(nitive impair)-25 (ment. Cochrane Database Syst Rev 2006:CD001747.)]TJ
0 Tc 0.155 Tw -1.6875 -1.37125 Td
[(12.)-500 (Minett TS, Thomas A, W)40 (ilkinson LM, et al. What happens when)]TJ
-0.013 Tc 0.013 Tw 1.6875 -1.24625 Td
(donepezil is suddenly withdrawn? An open label trial in dementia with)Tj
-0.011 Tc 0.011 Tw T*
(Lewy bodies and Parkinson\325)Tj
-0.0108 Tc 11.11118 0.00001 Td
(s)Tj
-0.011 Tc 0.62807 0 Td
(disease with dementia. Int J Geriatr Psy)Tj
0 Tc 15.49039 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.22965 -1.24627 Td
[(chiatry 2003;18:988)-25 (-93.)]TJ
0 Tc 0.10699 Tw -1.6875 -1.37124 Td
[(13.)-500 (Bickel U, Thomsen T)75 (, W)80 (eber W)90 (, et al. Phar)-25 (macokinetics of galan-)]TJ
0.002 Tw 1.6875 -1.24625 Td
(thamine in humans and corresponding cholinesterase inhibition. Clin)Tj
-0.02499 Tc 0.013 Tw T*
[(Phar)-25 (macol Ther 1991;50:420)-75 (-)-25 (8.)]TJ
-0.009 Tc 0.009 Tw -1.6875 -1.37125 Td
[(14.)-491 (Marino MR, V)110 (achharajani NN. Drug interactions with irbesartan. Clin)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(Phar)-25 (macokinet 2001;40:605)-25 (-14.)]TJ
0 Tw -1.6875 -1.37125 Td
[(15.)-475 (Iraqi A, Hughes TL. A case report of paranoid delusion with galantamine)]TJ
0.013 Tw 1.6875 -1.24625 Td
[(use \(letter\). J Am Geriatr Soc 2005;53:2036)-25 (-7.)]TJ
0.01601 Tw -1.6875 -1.37125 Td
[(16.)-475 (Brembilla-Perrot B, Regent MC, Hanesse B, et al. [Paroxysmal atrioven-)]TJ
-0.015 Tc 0.015 Tw 1.6875 -1.24625 Td
[(tricular block due to anticholinesterase therapy]. Arch Mal Coeur V)110 (aiss)]TJ
-0.02499 Tc 0 Tw T*
[(2004;97:1265)-25 (-7.)]TJ
0.013 Tw -1.6875 -1.37125 Td
[(17.)-475 (Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1)35 (157-)-75 (65.)]TJ
0 Tc 0.04401 Tw 0 -1.37125 TD
[(18.)-500 (Baraka A, Harik S. Reversal of central anticholiner)20 (gic syndrome by)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.24625 Td
[(galanthamine. JAMA 1977;238:2293)-25 (-)-125 (4.)]TJ
-0.021 Tc 0 Tw -1.6875 -1.37125 Td
(19.)Tj
0.021 Tw 1.66605 0.00001 Td
[(W)80 (ang MH, T)70 (seng CD, Bair SY)130 (. Q-T interval prolongation and pleomor-)]TJ
-0.01401 Tc 0.01401 Tw 0.02145 -1.24626 Td
[(phic ventricular tachyarrhythmia \(\324T)70.4 (orsade de pointes\325\) in or)20 (ganophos-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.24624 TD
[(phate poisoning: report of a case. Hum Exp T)70 (oxicol 1998;17:587-90.)]TJ
-0.015 Tc 0 Tw -1.6875 -1.375 Td
(20.)Tj
0.015 Tw 1.68964 0.00001 Td
(Fitzpatrick AP)Tj
-0.0152 Tc 5.55309 0.00001 Td
(,)Tj
-0.015 Tc 0.48475 0 Td
(Lee RJ, Epstein LM, Lesh MD, Eisenber)Tj
-0.0152 Tc 15.86827 0.00001 Td
(g)Tj
-0.015 Tc 0.73477 0 Td
(S, Sheinman)Tj
-0.017 Tc 0.017 Tw -22.64302 -1.25002 Td
[(MM. Ef)21.1 (fect of patient characteristics on the yield of prolonged baseline)]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(282)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0.013 Tw 8 0 0 8 60 749.5293 Tm
(AA Fisher and MW Davis)Tj
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
38 0 obj
<</BaseFont/DNFGOS+Helvetica-Bold/Encoding 35 0 R/FirstChar 32/FontDescriptor 37 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 278 0 278 278 556 556 556 556 556 0 0 0 0 556 333 0 0 0 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 778 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 0 278 889 611 611 611 0 389 556 333 611 556 0 556 556 500]>>
endobj
30 0 obj
<</BaseFont/OQKIVY+Helvetica/Encoding 27 0 R/FirstChar 32/FontDescriptor 29 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 584 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 0 584 0 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 667 944 667 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 222 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 1000 0 0 0 222]>>
endobj
27 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 40/parenleft/parenright 43/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 61/equal 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 208/endash/emdash 213/quoteright]/Type/Encoding>>
endobj
29 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 28 0 R/FontName/OQKIVY+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
28 0 obj
<</Length 5608/Length1 5608/Subtype/Type1C>>stream
  OQKIVY+Helvetica   @ø øøøøû:ûtú|ú7
 ‹‹
 ‹‹   ó   ï  Š¬  Ç €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  J  " M F Y B O E S  ' J T I . D 8 % W V U P G N Q  5 C 2 H  Z X [ 	 $ * 
 3      L / (     #   K R    1 0 + , &  6   o ) ‰ - 4 7 9 ! L   < Q ® ëw¹QTw™M¨ú>ƒ«éašù]mŠäPÒNŒ³ì	I	^	š	ü
|
Ó
êh›Æ0¨ïi
;VŒë$Az¼DušJm‘§Öí…®ê¡œ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğü@ vùawÎã÷/ùa3ıa-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;û* vøŸw˜ørøûL÷ ÷E÷“û ûûMû÷Mû÷Bû“ûKû ÷÷÷Y÷ûY-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³Ÿ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖ-|×cvø_Ù÷Hw®å÷±ã4â:Üyø†ùaú4û¡‰Î[d¡Eû7&û5ûEäû÷!Ï»§Å­yDü„÷‰ûTD24UØ÷÷ºËêæ¿>ûûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙüd v÷Ùá÷pááìøÚùáü„ıaì÷Ù÷ôáûô÷pü@ vøŸw÷íÎã÷/øÿí3)ãüÿøŸ3üŸû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹ó- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé÷K vùawÔè.æøŠé/çäùŒùaûû_üñ‰ûaøñûıaèø<ÔÇ‰Æ‹Çè÷_üïë÷]øğäèŠû	Šº;‹‹‹üZû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™÷º vùaw›ú"ú2ùa ûüÛ‰û4øÛ"û6üÛ‰ûøÛ#÷Oıağ÷:øçŒ÷7üèñÓ‹İø½İÜíøîù5ø÷gû÷ûJû·ıa÷³÷R÷÷÷z(…ûA< ûûOø½÷I÷5Àûûû* vøŸw“øwøøŸ+û(ü=‰Šûø>'÷RüŸè-|×cvøŸwÏâ÷‰ã8Şôø|øŸø3û´ TH2Hi²×÷ï4ü%ÉOöÛ´¢Ñ¸ô=ü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûü vøUÕ÷awßã÷˜øUÕ3Ì¶›°“”Š‰ÚŒw€Œ‚/_f=1EAÑüUãøU÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæ-ûLv÷R×ø#Ú{wÅŞ8ã3ß÷±åéø™÷¨÷24ôûH^qL`‰ùÔ8ılåã÷˜Wµ®yÈ÷#ã÷÷H1…ûX?0ã2UĞ÷÷!¼Õçê¼Jûü‹õâó÷Sõ#!d vùà÷•ëøçùàüÙ6÷‡ıëù-{Øcvø`Ù÷GwÅã3ß÷±åzø™÷¨÷24óûMZqTc‰÷˜3ıaŞÌöN¸¯wÎ÷å÷÷D1ƒûW?13TÒ÷÷½×æê¼Iû÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûeû!û-ûuûv÷ û,÷fÓÃš¬Ã÷6¼Å)ÖÑÖ­è‹÷(/o>WU1ÑZOÕRa{q†e‹û(%÷
÷A÷Dï÷	÷+÷*ïû	ûD-ûnÓ÷×ø!Û|w³æ@ã÷Ÿã7ß9İÔ€ø‡¶øt9@ù ‰Ì^^¤Hû4"û0ûDäû÷Òµ À«ö uûcZûHg¤Ä}3"œÍZ÷÷7Õİ÷Gù 7÷bûWH/5UØ÷÷»Îçé½Cûü‹õ6vâóX¾Ğ÷S“íà#!ĞÀàŠHsc]Ó›«»æû*ûjÚù&w–øqø|øŸ+û!ü?‰ûø?(÷Vü¬bû‚d‹v|‘v<…›—ˆœò› ÷_Øï÷œ–Ş÷‚Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æû*‹ÓøÕªøIøhÓûÕ÷ÍøÕü)A÷¶ûÎüFûÑûMvú>wÏè÷¿ûb<÷2P÷÷J÷D³÷ë÷;OûûB]ûû=ûVÑûòû0Ówáøİà·îøHç5éèù;÷œ-ûqCHûû&8÷÷R÷Gçö÷+ğïÏV*¤ç÷*s!àû7ûaûû%ûxû‚÷û%÷\è÷?÷	õ÷F¤ü vùawæì÷Pùa*ıaûÑûNvú>w÷@è÷÷÷VE÷$÷0QÚû2ÆûûJûDcû+û;Ç÷÷B¹÷÷=Ó v÷ÇŞ÷ŠÜãëøîù>›oš…—‰¸…÷‡×y©K§Ö¹¤¶‹à‹÷6Ğû*‹ûßıaë÷Ç÷æ®i.ûŒ}˜R‚ø™6[a*ûv÷Š÷‡Ş¸a>-xÚ÷¢×÷oÙ±èEæ÷ŒæGèêø˜÷`ÙhÀ;²ìË¬¥´Î÷5Õûû7?ûI¨aÍmò5ck[/ûî4÷!÷$éã÷ìû÷ÑHV[BEW»ÌÌ¹´ÑÜ¾cKò¢ûÚ5XZ1.QÁâ×ÇÀàåÄV9-x×÷ĞÚ÷*á«å÷½èø”÷x÷(ëûTfk^ª÷V÷½áûÿWüÖ†µ¼®À‹æÌK1*LJ/;\²Ù|1ûœ×K÷÷1ìé÷-ûÑ v÷{å·÷ˆ÷´÷{åûˆ1- vø†Ò÷w÷œêğø†÷7ü†êùREp$qxû€-‹İø±Ú¥î:â÷¯çèøİü˜Ë»³Æ«Ô³ïÂã¼÷÷3ŞûØû3?$û)â÷‘¸ÁåàÄW=Dmk&Q/VèûFc5…ûû* vøŸw÷jwÎàø‰ûh÷Û÷\÷Xûûvûqø36ıaà÷ZÔÍ÷7ûœÓ vùaw×èøêùùa,ü×‰ûúø×ûıaèøØøüØ÷xŞ`v÷ÁŞ÷Ÿà»ïøeå|ùSøûÎ8÷tˆ@gqfüPcJm8û09ñ÷V÷Eé÷÷'÷ ĞY&«è÷(oûãû7ûbûû,ûûo÷û)÷TöØ®ØÉ|£.-xÚ÷ÉÚ÷EÚ±ä2ò÷§àAåòø™÷q÷1èû@VpOdˆ•÷?Çæñ‹ìË³fC˜à†Ç~«i­e²Q¢R‹û5‹*û#‹û‹ûváû÷7‹ê÷ìñ÷1†0RJ94OËççÄÈàãÃP--wÛøÇÚ°è÷ºèø™÷é÷}6÷û/û/6ûû}ûzâû÷-÷-â÷÷z.ûKX)++Xí÷K÷O½êìì½+ûN-xÚ÷œÔ÷wÚ­ç÷ªåIéôø÷bŞi»8­øÃ ¬¿Î÷6Õûû(FDû3ƒá÷ “²¶ãİ½`DAYd,~…‹z?Œ›“‹ô÷Âc39MU+*`¹÷‡/û6™ÓC÷(÷/îã÷- v÷>×ø]w÷ßãø÷>×%ø]BûÕüR4÷Æû>ã÷>3×ûu÷t÷ÔŒœ‹Ş÷Ù÷rİÔì÷ØëMëøù÷làg»-±Í­©»Ğö:ÓûûÎıa÷Êô÷%ëá÷øû÷Ë?Ye(ûC÷r÷Cï¼gCô­ûÍ7U\*ûc÷÷R÷Åb;ü@ vøøôÀóX¾Ğ÷1ù ìà#"ĞÀàŠHsc]Ó›«»æüvù‡wz÷Ì÷»ùtIûŠı‡Îü@ûeÙù"w÷íÎã÷/øÿí3)ãıLøì3üâUTyA‡œ‹šè´´æ-ûNv÷T×ø"Ú|w®æ÷­â7ß8ŞÙø‚ûcùn8A‰üÉa\¦Gû4"û1ûGãû÷!È³Ÿ¼³û™úøYûUF14VØ÷÷ºÍçé¾Aûü vø/õâóX¾Ğ÷Sø/õà#!óü'í#!ĞÀàŠHsc]Ó›«»æü‹õ÷Åõâó÷Sø/õ#!óü/õ#!- vøíá÷êøøöØüy5ø@1W:UûOûl/}#ê­÷4¢ÒÁ÷ Ä÷ÀÚĞØœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûdû"û-ûuûv÷ û,÷f÷e÷ ÷,÷v(ûA%û
û(û)%÷
÷A÷Eï÷÷+÷*ïû	ûDû*xİù"wœå÷sìø?÷VøŸ*ü¥7fb>Bg²Ú½1DûØG÷÷ÖÙ÷œ vùawÖìù)ûÇø@÷¾÷µûûïûğ÷ğ*ıaì÷÷÷÷ûüœ‹á÷…à÷pàáìøüáüE÷…øàü÷pø<àüıa-xÔ÷IÚ÷ËÙµå9â÷¦ñ4âòø•ø÷k7÷û6û1+û%ûà2÷ÙÁ¦Ä®‰nûX`H)‹êEa´Õ„4û”ÔI÷ÖÆ¨Åµ½Î¨÷÷ô%í#XR.6YÁçñ¿ÊßâÃP0ÓxáùwÚìøëù÷‘ød+üYûFCûûIÓ÷øV*ürû1÷ &÷<÷F÷ò÷=I v÷Ô÷Ô²øŒø³÷ÒÔüŒBøŒû`ÔüŒBI v÷lÓ÷”Óø³÷lÓûk÷mCûmûmC÷mûlÓ÷l- v÷ƒÕ‹øÀøÀ÷ƒÕüÀAÓ v÷áâ÷½wØì*íø
ìôùùa*û½ü÷½*ıaìí÷áø
ûá÷ò v÷ƒÕ‹ú|ú|÷ƒÕş|A-‹áùw×ìø¬áûÿù*ıaœxŞ÷‹Ù`å÷nŞ¼æGè÷êæCèÕøÿ÷YïQÏ#£öûaºQ˜n¬‹½ÖÊºğ÷ÇZ*”æ÷/€3ÕûBû2,7û3¿SñsÙ÷&h÷
o¯p‹N4L_ûûDÆöˆ0ŒD•e©dG¿Ùi÷ ÷KöÛ÷œ vùawŸùùùaûû^ü÷‰ûbø÷ ÷šıaòœ vùawùùûø÷ƒ÷ñûûJû¦ûJ÷¦û÷„ûñû”ü÷÷[÷¼÷Uû¼øxÉèÌJÔ÷¸ÓñÈ÷'Ô×Şø:Ìßùöø>÷Cû*÷ûVûeû:û:ûdûk÷:û:÷l÷÷Î÷ÊI@H8d/ûBû÷÷C÷K÷÷÷A÷3÷ûû$ FûCyŠšš¤§éÈ÷cGwMlÄj W‹û$ûû,5ÍAØ¶¬˜½»a v±®À¢¬´ÒÆ±İèÿû“y*>%A[j³ÄìÕíÔ¹²`Yu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
35 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period/slash/zero/one/two/three/four 57/nine/colon 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 120/x/y/z]/Type/Encoding>>
endobj
37 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 36 0 R/FontName/DNFGOS+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
36 0 obj
<</Length 4493/Length1 4493/Subtype/Type1C>>stream
  DNFGOS+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      y²  f €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  8  $ B T F  3 Q P S U 0 # + & 5 * 7  " 4 6 . : % / - , 8 C M   )  1 2 D N Z G V  J O [ ' E H I     ( W  Y :   T Ô> £sºÿ;?k¤Îõ0½ó3_¦Õğ"í2Gq—Ü	C	‘

I

È
åU‚«†ÍBä`Æñ=uÓx÷øƒ÷·ùù?÷‰û)*n_f6ûHç÷,÷4Íæ÷
Şµi1§÷(÷-~ûğûAû]ûû'û|û|÷û$÷^÷;öæ÷A°-}ïJv÷zÜ÷÷¨÷÷Q÷|ø¡ u’‚£¿÷´ë;Åûû0FUû€÷½§£ÀÊ¨x`t|}i†ûx${XR‹*ü.ËMëÓ²ÆÉ|Œq”püz÷SRS[K`q¤²»¡Ò˜Ğ˜ˆŠ©œ-}õ÷ğõ©÷#û÷û÷÷a÷ Ôøš÷9÷dûá?‹ê©«ÀÇ¨uZ‘÷÷„;Åû-û;D ûX÷İÊ‹3ggxVÌ=h¢Âˆäû#ûëE÷0÷#æĞ÷-}÷÷æ÷÷¢÷#û#÷ ÷p÷#ôø¢÷x¤÷P2ôû5û4.%ûDûIç&÷9÷ÚÂ÷¯û#cyny\ìAdµä„ô÷pæûmÚ˜«¬ÊÊ¯f@•üÓ v÷®÷÷T÷×÷(÷¸÷(ù9s”„À÷H€©:¯Õ©¯Äß÷3ÚûûÿŒıa÷'÷®÷/îšyû
ŒFo˜Zø†Ign:ûC÷T÷OÎ±hMdûNv÷U÷÷Ù÷{wÉ÷û÷!÷{÷#êøÕ÷¤÷82÷ûAcsF^‰úØûıvæ÷!÷¦Œ­R¹rĞ‹÷á÷÷Dû#‚)^KEê?\Æé÷´ÆÙÖ·O$d}÷	÷Ù÷
­÷#÷•÷#øÕ÷÷?!÷û9û:!ûû?ûAó ÷<÷;ó÷ ÷@û# _S76_Ãöô¸ÄßŞ¸R"û™ vø(÷"|wË÷û÷ ğøø%÷"†‹Jgp<_‰ğæûü§è÷ ÷¨ß··ß–”Š‰ŸûÑ…õ÷ßïİ÷ ÷Èˆõ‰|„Š^„‘±÷³áï5÷%û û%C'ÓûÕ7³kò™Œ«÷x÷øŠ÷·ùFùr÷ú÷mû÷6ûvûuûû4ûoûn÷	û3÷x÷t÷÷4÷mû*Œû0A,ûûAê÷0÷/Öë÷÷Ö+û/Ó‹÷÷U÷÷0÷×÷$÷®÷#û÷)ôù0÷màmº:±øÊ®¤´Î÷5Óûûğıa÷ÅŞÈ•­ôÏ±´ÑÛøû:÷ÁXdmGûC÷0÷?×®tWôœûºKafCûM÷U÷SÏ³iQ-y÷øúw¡÷÷A÷*øw÷dø‘û*ü‘?snNKs±ò¦ûlûOÌD÷A÷'×Ø÷)œ‹÷÷O÷÷+÷×÷'ù ÷ü!÷O÷ğ÷ûğ÷+ø÷ü¢ıad vøã÷÷z÷+øèøã÷üÚû÷lüã÷+øãü vùawË÷*÷jùaû*ıaœ vùawùùùaû/û0ü³‰Šû.ø´û4÷†ıa÷#ûÑ‹÷%÷r÷%ç÷*÷†ø÷%û*û%÷*ü÷%û*û%Ó v÷'÷øQwŸù;ùOû‘ùaûAû‘ıa÷1½÷'÷¹û'3÷¤ûLç÷°œw÷÷I÷$÷'÷6÷²÷"û÷÷¥÷#û÷%Õù	÷lòSÃû¬öûC·S™v ‹´À¼¬×æºhB•÷#÷$„ âû;ûA&8û"û*õo÷nÙØyîtªv‹^NYl&,Z°Ùƒû"C™d±a¿Såk÷‹÷@‹÷ç‹÷$Óx÷øöwÓøÖù÷øgû,üm/[^*;[Âåøeû-üpû7õ*÷F÷Tñè÷D÷K vùawĞ÷ ø4÷ùùaûlûüÉˆûøÉûoıa÷ øì÷üì÷(÷øìüìœ vùawšùùùaû=û!ûËû*÷ËûD÷ŒüSû¢÷+÷¡Ó‹÷øi÷×÷'÷È÷,ù?ø÷n'÷ûSûĞıa÷Ë÷J÷÷%÷{û,û(M0'û&øi÷$÷À@û/Ó vùawĞ÷ ÷Ä÷ ù!ùaû üˆ‰û±øˆû1ıa÷ ø”÷¸ü”d‹÷øßw×øøÚ÷ûøøßû*ıaÓ vùawâùùeûÈø=÷·÷¸ûUû¥ûµ÷µû+ıa÷+÷‡ÑÓ÷qûÏ÷º vùaw÷·Ï¬ÙÚ¬Ôú4ùaû+bûCbûBgûD‰h÷UƒB÷èû3Nû¾”¿Zû«‰h÷St7÷ùû3÷_ıa÷ ±÷N¶÷N©÷PªûO³ûP´ûM÷#d}÷;vø=÷÷>wÈ÷ û ÷÷ƒ÷#zøÕ÷¥÷72÷ûE]rQe‰÷‘û ıa÷ÎöS®»rĞ÷á÷÷Dû#*]JE@[Éìô·Ç×Ö·O%ü vùawĞ÷ ÷eùaû ıa- vø}î÷w÷÷!û÷èøùZû8Td w(Ğ÷<ü}ü‹÷%Ë÷*÷j÷%û*û%Ó v÷Õ÷÷¤wÒø×ùùaû*û¤û«÷¤û*ıa÷*÷Õ÷«ûÕü‹÷%÷(Í÷j÷û*û%ß„DvrTxVğ£»Äõœ v÷—÷÷h÷øq÷)ùø€÷4áûûÜıa÷*÷—÷@÷çé÷û)‰Cfg@û÷h÷
í®o?÷x÷øŠ÷·ùHùt¨=Õ¼Ê¦á‹õ÷mû÷6ûvûuûû4ûoûn÷	û3÷xËÎ©Àß;Bø.N~Wvb@Ò>:ÔFsp…l‹ûAê÷0÷/Öë÷÷Ö+û/-}÷÷Û÷
­÷$÷`÷!øŸ÷Vû!KjnSHgÁ÷õ³ÅÕº©pP˜÷!÷ƒ+Ôûû71$ûOû?å(÷/÷åØ÷÷ƒ vø?÷
û	÷
|wË÷ û ÷÷E÷÷>÷ ëùÌø÷CĞûO`qPfçÎ_jCF^pJg‰÷Øûü§ë÷ ÷×Ğ¨¯ÄÉ¢n:ûÒ÷÷ÒëÓ«°É½¥m@ûÖ-ûi÷ùw•ø£ø­ø§û'û ü‰ûøû/÷Xü¾{K{|U‹…ˆ‹sûŠ§Š›÷	÷_ÑûÑ vøEíÜ÷á÷ ÷ÑøEí0 ¿‘“µ²÷h€‹q#XZ%_?)×üE÷ øEd}÷
8vø§wÍ÷ ÷[÷û÷ôø³ø§øûûÇB`\IOm¬Ì÷İû ûñûÍC÷Ö¾§È¯ô@üvùˆwj÷ë÷Êùuû	ûvıˆ÷ü vø§wŞ÷Ğ÷ ÷eøæ÷û û÷ üæø§û ü§d vø?÷|wÌ÷û÷ ÷]÷ôø´ø÷DÏûC_rH`‰ôØûü§ì÷ ÷ÄØµ¹ÑÇ¨iEû×û*‹÷÷Ä÷Ÿø^ør÷ûª÷ ÷Á÷üBû÷‘û£ûÊûd v÷Á÷÷7÷×ø‘øİøã÷ü‘ıa÷*÷Á÷Î÷ûÎ÷7d}÷;vø<÷÷?w­÷$÷|÷û÷zø¸ùaüûû“‰Ê^d Dû5û û;û@äû÷Ï¾¦Á®zHú÷˜&^Q=E^ÊìóµÆÖÚµR dûmõ÷ ÷
÷É÷|w³÷#÷z÷û÷Úø¼¨øŠû<‰üËmX©Dû4!û<û?â#÷!Ğ´£Ä«‡L4hh>Kt˜´û,#—ŞS÷'÷’÷.çû÷„*eR:G`Çéê¶ÇÎ×·J1d vø@÷÷>wÌ÷û÷ ÷]÷ôøµø÷CÑûCVnUoˆ÷‘ûıaì÷ ÷Åß³²ÕÆ§jCû×-x÷÷÷÷÷©÷÷d÷$û÷ôø÷í÷Š9÷û<û(.-û*û á-÷Ë¯›¸¯ˆ‡ûcHB‹[p¢º„ûûœÜH÷÷8é÷÷{øû$÷?c[LId¸Ùß´¶ÇÏ²];-x÷ø÷«÷$÷_÷$øŸ÷î÷Œ=÷û<û;=ûûŒûØû÷<÷=Ø÷÷û$ŒûRqK?@qË÷R÷P¥ËÖ×¥KûP-‹÷øh÷
«÷÷]÷ ø’÷ûÈ¨Ä÷ÏÊÅÀ»¨Â‹Ú‹÷(ãû'‹û'‹<6†û9÷î¥¬ÒÇ³bL4Gkû4û*jS„û-x÷÷mï÷O÷¦÷û÷÷M÷ û÷$êø˜÷gÜdÆG£ìÈ¯¢±Î÷0Øûû1:û&Š÷Ü­­ÅÂ®hTIel:v'ò÷‰²q<K^]NHl°â†ûû)‰æ3÷,÷(ïè÷÷x÷4v÷÷÷u÷ø×÷xù[øû½û÷9øû oQY*ûAç÷0÷4Ùì÷×Æ_B¡÷(÷)xûæûCûiûû(ûzûv÷û+÷YíÌ«ÙÈx™0- vø§w˜ø¤ø±ø§û'ûü‰ûøû/÷Tü§÷&- v÷0÷øQw÷Æ÷ û÷èø¡÷0÷<øQû4û—üDûĞ÷«û0÷ ÷0ûø3Š'Š#%ûEÈ÷E÷Æ- vø§wšø ø¯ûH÷¢÷B÷™û94û.1÷.û>÷Bû™ûHû¢÷<ç÷4çû4wŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
84 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
85 0 obj
<</OP false/OPM 0/op false>>
endobj
92 0 obj
<</A 93 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
93 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
78 0 obj
[94 0 R]
endobj
79 0 obj
<</Length 13667>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.00301 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(weakness, delirium, syncope, hypotension, tachypnea, QT)70 (c)]TJ
-0.01601 Tc 0.01601 Tw 0 -1.23809 TD
(interval prolongation, and arrhythmias, indicating overac-)Tj
-0.006 Tc 0.005 Tw 0 -1.2381 TD
(tivity of muscarinic and nicotinic sites of autonomic and)Tj
0.006 Tw T*
(somatic nerves, as well as of the central nervous system.)Tj
0 Tc 0.011 Tw 0 -1.23809 TD
(This may be due to a significant upregulation of acetyl-)Tj
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(choline receptors caused by decreased synaptic concentra-)Tj
0 Tc 0.149 Tw T*
(tion of acetylcholine due to abrupt discontinuation of)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(galantamine after prolonged exposure to the drug. )Tj
-0.00301 Tc 0.00301 Tw 1 -1.22381 Td
(Other causes for clinical deterioration were excluded.)Tj
0 Tc 0.01401 Tw -1 -1.22381 Td
[(There was no metabolic abnor)-25 (mality)65 (, electrolyte imbal-)]TJ
-0.01601 Tc 0.01601 Tw 0 -1.22381 TD
(ance, or signs of infection. Galantamine is the most likely)Tj
0 Tc 0.16499 Tw T*
(cause, given that it was the only medication recently)Tj
-0.024 Tc 0.024 Tw T*
[(restarted. The patient\325)55 (s condition resolved with discontinu-)]TJ
-0.004 Tc 0.004 Tw T*
(ation of galantamine and irbesartan. The latter may con-)Tj
-0.034 Tc 0.02299 Tw T*
[(t)-10 (ribute to hypotension but is unlikely to cause delirium, syn-)]TJ
-0.03101 Tc 0.02 Tw T*
[(cope, QT)70 (c interval prolongation, or arrhythmia \(MEDLINE)]TJ
-0.008 Tc 0.007 Tw T*
[(searched\). Drug interaction is a theoretical possibility)65 (, as)]TJ
-0.017 Tc 0.01601 Tw 0 -1.22382 TD
[(galantamine, irbesartan, and simvastatin under)20 (go metabo-)]TJ
-0.02499 Tc 0.01401 Tw 0 -1.22381 TD
[(lism via the CYP3A4 isoenzyme. However)40 (, the role of this)]TJ
-0.022 Tc 0.022 Tw T*
(enzyme in metabolism of irbesartan is minimal,)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 250.9888 488.3696 Tm
(14)Tj
ET
BT
/T1_0 1 Tf
0.022 Tw 10.5 0 0 10.5 258.9509 485.6196 Tm
(and sim-)Tj
-0.015 Tc 0.015 Tw -18.9477 -1.22381 Td
(vastatin was not ceased. Therefore, this mechanism is not)Tj
-0.02499 Tc 0.013 Tw T*
(likely to be significant.)Tj
-0.02299 Tc 0.022 Tw 1 -1.22381 Td
(Nausea, vomiting, and diarrhea, which were seen in our)Tj
0 Tc 0.036 Tw -1 -1.22381 Td
[(patient, are the most common adverse ef)20 (fects of AChIs)]TJ
-0.013 Tc 0.013 Tw T*
(linked to muscarinic enhancement. Urinary incontinence,)Tj
0 Tc 0 Tw T*
(hypotension, and bradycardia were other muscarinic ef-)Tj
-0.00101 Tc 0.00101 Tw T*
[(fects in our case. W)80 (eakness, tachypnea, initial \322nor)-25 (mal\323)]TJ
-0.02 Tc 0.02 Tw T*
(heart rate \(followed by bradycardia\) may be considered as)Tj
-0.01199 Tc 0.01199 Tw T*
[(mainly peripheral nicotinic ef)20 (fects, while CNS ef)20 (fects in-)]TJ
-0.01801 Tc 0.01801 Tw T*
(cluded delirium, restlessness, and agitation. There are few)Tj
-0.02499 Tc 0.02499 Tw T*
(case reports of delirium,)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 156.3089 347.5696 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 164.6367 344.2696 Tm
(syncope,)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 6 0 0 6 199.5851 347.5696 Tm
(16)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 207.9129 344.2696 Tm
[(and QT)70 (c interval pro-)]TJ
0 Tc 0 Tw -14.08694 -1.22381 Td
(longation)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 99.6621 334.7196 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
0.015 Tw 10.5 0 0 10.5 105.4477 331.4196 Tm
[(associated with galantamine, and the mecha)2.4 (-)]TJ
-0.02499 Tc 0.013 Tw -4.32835 -1.22381 Td
[(nisms of these adverse ef)20 (fects remain unclear)55 (.)]TJ
-0.021 Tc 0.021 Tw 1 -1.22382 Td
[(Although exposure to anticholiner)20 (gic medications is as-)]TJ
-0.019 Tc 0.019 Tw -1 -1.22381 Td
(sociated with delirium,)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 152.3537 296.1696 Tm
(17)Tj
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 160.7524 292.8695 Tm
(and galantamine has been shown)Tj
-0.021 Tc 0.021 Tw -9.59547 -1.22381 Td
[(to produce ef)20 (fective reversal of this syndrome,)]TJ
ET
BT
/T1_2 1 Tf
-0.019 Tc 0 Tw 6 0 0 6 246.3565 283.3196 Tm
(18)Tj
ET
BT
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 254.7294 280.0195 Tm
(in our pa-)Tj
0 Tc 0.16499 Tw -18.54566 -1.22381 Td
[(tient, galantamine precipitated agitated delirium. Irre)7 (-)]TJ
-0.017 Tc 0.017 Tw 0 -1.2238 TD
(versible inhibition of acetylcholinesterase by or)Tj
0 Tw 18.25565 0.00001 Td
(ganophos)Tj
0 Tc [-0.4 (-)]TJ
-0.017 Tc 0.01601 Tw -18.25565 -1.22381 Td
(phorous insecticides causes confusion and coma.)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tc 0 Tw 6 0 0 6 257.9933 244.7694 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.0166 Tc 10.5 0 0 10.5 266.4207 241.4695 Tm
(A)Tj
-0.017 Tc 0.95528 0 Td
(case)Tj
-0.02499 Tc 0.019 Tw -20.61439 -1.22381 Td
[(report described a 77-year)20 (-)-75 (old man with early Alzheimer)-35 (\325)56 (s)]TJ
-0.007 Tc 0.007 Tw 0 -1.22381 TD
(disease who developed paranoid delusion after 4 days of)Tj
-0.02499 Tc 0.013 Tw T*
(galantamine use.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 126.4856 206.2195 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01801 Tw 10.5 0 0 10.5 70.5 189.9195 Tm
[(All 3 AChIs used in Alzheimer)-35 (\325)55 (s disease, according to a)]TJ
-0.008 Tc 0.008 Tw -1 -1.2381 Td
(recent Cochrane review of pooled data from randomized)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(controlled trials, have demonstrated a significantly higher)Tj
0 Tc 0.06599 Tw 0 -1.2381 TD
(incidence of syncope compared with placebo \(3.4% vs)Tj
0 Tw T*
(1.87%\).)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 93.238 141.2194 Tm
(1)Tj
ET
BT
/T1_0 1 Tf
0.216 Tw 10.5 0 0 10.5 101.132 137.9194 Tm
(An AChI edrophonium has been used as a)Tj
0.021 Tw -3.91733 -1.23809 Td
(provocative agent for inducing syncope during head-up)Tj
-0.02499 Tc 0.006 Tw T*
(tilt-table testing.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 123.894 115.2195 Tm
(20)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.006 Tw 10.5 0 0 10.5 132.0242 111.9195 Tm
(In the majority of published studies, syn-)Tj
0.01199 Tw -6.85945 -1.2381 Td
(cope was associated with donepezil and was usually due to)Tj
-0.011 Tc 0 Tw 0 -1.23809 TD
(new-)Tj
-0.00999 Tc 0.00999 Tw 2.03191 0.00001 Td
(onset bradycardia. However)Tj
-0.0105 Tc 10.95421 0.00001 Td
(,)Tj
-0.00999 Tc 0.48946 0 Td
(in two-thirds of 16 pa)Tj
0 Tc 8.4774 0.00001 Td
(-)Tj
-0.008 Tc 0.008 Tw -21.95298 -1.23811 Td
(tients treated with donepezil and hospitalized for evalua-)Tj
0 Tc 0.103 Tw T*
(tion of syncope, its cause was considered unrelated to)Tj
0 Tw 0 -1.2381 TD
(donepezil.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 103.4407 50.2195 Tm
(21)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.05 Tw 10.5 0 0 10.5 112.5865 46.9195 Tm
(There is one case report of syncope due to)Tj
-0.022 Tc 0.022 Tw 19.56319 65.13335 Td
(complete atrioventricular block that occurred after the first)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(administration of galantamine.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 438.9686 721.1196 Tm
(16)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 328.5 704.9197 Tm
(In our patient, the first syncopal episode was observed)Tj
-0.02299 Tc 0.02299 Tw -1 -1.22857 Td
(14 months after he started galantamine and was associated)Tj
-0.01199 Tc 0.011 Tw 0 -1.22857 TD
(with hypotension and sinus bradycardia. The next synco-)Tj
0 Tc 0.213 Tw T*
(pal episode occurred 3 weeks after galantamine was)Tj
-0.024 Tc 0.024 Tw T*
[(restarted and was associated with severe hypotension, QT)70 (c)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.22858 TD
(interval prolongation, and arrhythmias. Although our pa-)Tj
-0.00101 Tc 0.00101 Tw 0 -1.22857 TD
(tient had coronary artery disease, he developed syncope)Tj
-0.02499 Tc 0.013 Tw T*
(only when he received galantamine. )Tj
0 Tc 0.231 Tw 1 -1.22857 Td
(The most extraordinary feature of our case is the)Tj
-0.019 Tc 0.019 Tw -1 -1.22857 Td
[(m)1 (a)1 (r)1 (k)1 (e)1 (d)1 ( )1 (Q)1 (T)71 (c interval prolongation with potentially serious)]TJ
-0.024 Tc 0.024 Tw T*
[(cardiac arrhythmias. Our patient had a QT)70 (c interval of 503)]TJ
-0.004 Tc 0.004 Tw T*
[(msec \(by Bazett\325)55 (s for)-25 (mula\), an increase of more than 60)]TJ
T*
(msec above the drug-free period. According to the Food)Tj
-0.00301 Tc 0.00301 Tw T*
(and Drug Administration and the Committee for Propri-)Tj
-0.022 Tc 0.022 Tw T*
[(etary Medicinal Products, any QT)70 (c interval over 500 msec)]TJ
-0.005 Tc 0.005 Tw T*
(or any increase of more than 60 msec is a cause for con-)Tj
-0.01801 Tc 0.01801 Tw T*
[(cer)-25 (n for the development of torsade de pointes. In 92% of)]TJ
-0.02299 Tc 0.02299 Tw T*
[(1)35 (16 torsade de pointes cases related to treatment with non-)]TJ
-0.007 Tc 0.007 Tw T*
[(cardiac drugs, QT)70 (c intervals were more than 500 msec.)]TJ
ET
BT
/T1_2 1 Tf
-0.005 Tc 0 Tw 6 0 0 6 546.0421 476.0198 Tm
(22)Tj
ET
BT
/T1_0 1 Tf
-0.03101 Tc 0.021 Tw 10.5 0 0 10.5 318 459.8198 Tm
[(Acquired or congenital QT)70 (c interval prolongation can result)]TJ
-0.028 Tc 0.01801 Tw T*
(in ventricular arrhythmias leading to syncope, seizures, and)Tj
-0.00999 Tc 0.021 Tw T*
[(sudden death. The Cochrane review of pool)-10 (e)-10 (d)-10 ( )-10 (d)-10 (a)-10 (t)-10 (a)-10 ( )-10 (f)-10 (r)-10 (o)-10 (m)]TJ
-0.021 Tc T*
(unpublished studies found that use of galantamine was as-)Tj
0 Tc 0.03799 Tw 0 -1.22856 TD
(sociated with a significantly higher rate of unexplained)Tj
-0.02499 Tc 0 Tw 0 -1.22857 TD
(death.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 341.788 398.6199 Tm
[(1)79.2 (1)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 349.6335 395.3199 Tm
(There has been one report of galantamine-associat-)Tj
-0.015 Tc 0.015 Tw -3.01271 -1.22857 Td
(ed QT)Tj
-0.0148 Tc 2.39789 0 Td
(c)Tj
-0.015 Tc 0.67915 0 Td
[(interval prolongation \(518 msec\) in a 47-year)20 (-)-75 (old)]TJ
-0.02499 Tc 0.01401 Tw -3.07703 -1.22857 Td
(schizophrenia patient.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 404.5016 372.8199 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01401 Tw 10.5 0 0 10.5 409.8647 369.5199 Tm
[(Another report described a 78)-25 (-year)20 (-)]TJ
-0.024 Tc 0.024 Tw -8.74901 -1.22857 Td
[(old man with Alzheimer)-35 (\325)56 (s dementia who developed a QT)70 (c)]TJ
0 Tc 0.011 Tw T*
[(interval of 477 msec a week after commencement of ri)1.1 (-)]TJ
-0.02499 Tc 0 Tw 0 -1.22858 TD
(vastigmine.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 363.8767 334.1199 Tm
(8)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.024 Tw 10.5 0 0 10.5 369.3551 330.8199 Tm
(Our patient did not have the confounding fac-)Tj
-0.01401 Tc 0.01401 Tw -4.89096 -1.22857 Td
(tors present in these 2 cases: use of psychotropic drugs in)Tj
-0.02499 Tc 0.01601 Tw 0 -1.22857 TD
(the first and hypokalemia in the second. He did not receive)Tj
-0.01199 Tc 0.01199 Tw T*
[(any other drugs that may precipitate QT)70 (c interval prolon-)]TJ
0 Tc 0.006 Tw T*
[(gation and did not have electrolyte abnor)-25 (malities or hy-)]TJ
0.033 Tw T*
[(pothyroidism. In our patient, QT)70 (c interval prolongation)]TJ
-0.011 Tc 0.011 Tw T*
(was associated with nonsustained ventricular tachycardia)Tj
0 Tc 0.01401 Tw 0 -1.22858 TD
(revealed by Holter monitoring 3 days after galantamine)Tj
-0.02299 Tc 0.02299 Tw 0 -1.22857 TD
[(was discontinued. Three weeks later)40 (, Holter recording was)]TJ
-0.021 Tc 0.021 Tw T*
(unremarkable. In our case, polymorphic ventricular tachy)Tj
0 Tc 21.95305 0.00001 Td
(-)Tj
-0.00101 Tc 0.00101 Tw -21.95305 -1.22857 Td
(cardia \(torsade de pointes\) could not be ruled out, given)Tj
-0.02299 Tc 0.02299 Tw T*
(that there was no ECG monitoring during the first days af)Tj
0 Tc 21.95295 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -21.95295 -1.22858 Td
(ter admission. )Tj
-0.017 Tc 0.017 Tw 1 -1.22857 Td
[(After or)20 (ganophosphate poisoning, QT)70 (c interval prolon-)]TJ
-0.009 Tc 0.009 Tw -1 -1.22857 Td
(gation with ventricular arrhythmias, including torsade de)Tj
-0.02499 Tc 0.02499 Tw T*
[(pointes, often occurs between the third and fifteenth day)65 (. It)]TJ
T*
(is unrelated to serum electrolyte imbalance and is associat)Tj
0 Tc 21.95278 0.00001 Td
(-)Tj
-0.013 Tc 0.013 Tw -21.95278 -1.22858 Td
[(ed with high mortality)65 (, especially sudden and unexpected)]TJ
-0.019 Tc 0 Tw T*
(death.)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 6 0 0 6 342.1898 101.92 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 350.5913 98.62 Tm
(The syncope experienced by our patient may well)Tj
-0.01199 Tc 0.01199 Tw -3.10393 -1.22857 Td
(be related to QT)Tj
-0.0116 Tc 6.30447 0.00001 Td
(c)Tj
-0.01199 Tc 0.6823 0 Td
(interval prolongation with dysrhythmia)Tj
-0.02499 Tc 0.013 Tw -6.98677 -1.22858 Td
(of torsade de pointes.)Tj
-0.013 Tc 1 -1.23333 Td
(Although our patient had no family history of long QT)Tj
-0.01199 Tc 0.01199 Tw -1 -1.23334 Td
(interval syndrome or sudden cardiac death, a genetic car-)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 347.0937 749.5293 Tm
(Prolonged QT Interval, Syncope, and Delirium with Galantamine)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(281)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tc 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
80 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
81 0 obj
<</OP false/OPM 0/op false>>
endobj
94 0 obj
<</A 95 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
95 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
74 0 obj
[96 0 R]
endobj
75 0 obj
<</Length 10649>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.019 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(Bazett\325)55 (s for)-25 (mula\) 4 days after discontinuation of galan-)]TJ
-0.022 Tc 0.022 Tw 0 -1.23809 TD
[(tamine and remained nor)-25 (mal thereafter \(T)70 (able 1\). A repeat)]TJ
0 Tc 0.07201 Tw 0 -1.2381 TD
[(24)-75 (-hour electrocardiographic monitoring 3 weeks later)]TJ
0.09801 Tw T*
(showed sinus rhythm with an average heart rate of 76)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(beats/min \(minimum 49, maximum 126\), ventricular \(n =)Tj
0 Tc 0.002 Tw 0 -1.2381 TD
[(626\) and supraventricular \(n = 260\) and ectopy)65 (. He was)]TJ
0.035 Tw T*
[(dischar)20 (ged, with an MMSE score of 21/30 on his usual)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.23809 TD
(medications except for galantamine and irbesartan. He re-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(mained asymptomatic for 6 months.)Tj
ET
BT
/T1_1 1 Tf
0.011 Tw 10.5 0 0 10.5 60 598.8197 Tm
(Australian Reports)Tj
ET
BT
/T1_0 1 Tf
-0.00011 Tc 0 Tw 10.5 0 0 10.5 70.5 577.8197 Tm
(A)Tj
0 Tc 0.037 Tw 1.00885 0 Td
(summary of cases of cardiac, neurologic, and gas-)Tj
-0.02 Tc 0.02 Tw -2.00885 -1.2381 Td
(trointestinal disorders associated with 3 AChIs reported to)Tj
0 -1.23809 TD
[(ADRAC \(to May 31, 2007\) is shown in T)70 (able 2. No cases)]TJ
-0.021 Tc 0.021 Tw T*
(of torsade de pointes were reported. There have been 5 fa-)Tj
0 Tc 0.36501 Tw T*
(tal outcomes associated with galantamine, 1)Tj
-0.00011 Tc 19.3934 0.00001 Td
(1)Tj
0 Tc 0 Tw 1.11455 0 Td
(with)Tj
-0.006 Tc 0.006 Tw -20.50795 -1.2381 Td
(donepezil, and 3 with rivastigmine, including 3, 6, and 0)Tj
-0.02 Tc 0.02 Tw T*
[(sudden deaths, respectively)65 (. When the number of reported)]TJ
-0.008 Tc 0.008 Tw 0 -1.2381 TD
(cases was analyzed per 100,000 prescriptions written, an)Tj
-0.009 Tc 0.009 Tw T*
(estimated 8.47 cases of delirium, confusion, or agitation;)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(3.76 of syncope; 2.82 of any type of arrhythmia or block;)Tj
0 Tc 0.063 Tw T*
(3.29 of vomiting; 3.76 of diarrhea; and 1.41 of sudden)Tj
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(death were related to galantamine. For rivastigmine, the)Tj
-0.008 Tc 0.008 Tw 0 -1.23809 TD
(corresponding figures were 14.10, 5.37, 1.30, 7.38, 3.36,)Tj
0 Tc 0.07201 Tw T*
[(and 0, respectively)65.8 (,)-322.4 (and for donepezil 4.77, 1.28, 1.27,)]TJ
-0.015 Tc 0.015 Tw 0.00001 -1.2381 Td
[(2.13, 1.28, and 0.51, respectively)65 (. These data suggest that)]TJ
-0.02499 Tc 0.02499 Tw T*
(use of galantamine may be associated with the highest rate)Tj
-0.01801 Tc 0.01801 Tw T*
(of arrhythmia and sudden death, with rivastigmine having)Tj
0 Tc 0.043 Tw 0 -1.2381 TD
(the highest rate of delirium, syncope, and vomiting; no)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
(sudden death was reported. The rate of reported adverse)Tj
0 Tc 0 Tw T*
(ef)Tj
0.13699 Tw 0.75659 0.00001 Td
(fects with donepezil was lower than that with other)Tj
0.037 Tw 23.81484 38.09523 Td
(AChIs \(except that sudden death was not reported with)Tj
-0.02499 Tc 0.00301 Tw T*
(rivastigmine\). The total number of reports per 100,000 pre-)Tj
0 Tc 0.01199 Tw 0 -1.2381 TD
(scriptions was similar for galantamine and rivastigmine)Tj
-0.01401 Tc 0.01401 Tw T*
(\(52.3 and 57.1, respectively\) but was about 2 times lower)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(for donepezil \(25.9\).)Tj
ET
BT
/T1_1 1 Tf
0 Tw 10.5 0 0 10.5 318 650.8197 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
0.01801 Tw 10.5 0 0 10.5 328.5 629.8197 Tm
(Although galantamine is widely used in the treatment of)Tj
0 Tc 0.01601 Tw -1 -1.2381 Td
[(mild-to-moderate Alzheimer)-35 (\325)55 (s disease and known to be)]TJ
-0.022 Tc 0.022 Tw T*
(well tolerated,)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 374.7861 607.1197 Tm
[(1)76.4 (1)]TJ
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 382.8135 603.8197 Tm
[(its choliner)20 (gically dependent gastrointesti-)]TJ
-0.01801 Tc 0.01801 Tw -6.17271 -1.2381 Td
[(nal adverse ef)20 (fects are well recognized and cardiac distur-)]TJ
-0.01401 Tc 0.01401 Tw T*
(bances have been reported.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 428.2039 581.1197 Tm
(5)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 433.7424 577.8197 Tm
[(T)71 (o our knowledge, this is the)]TJ
0 Tc 0.03 Tw -11.02308 -1.2381 Td
(first case report of a patient who developed withdrawal)Tj
-0.015 Tc 0.015 Tw T*
[(syndrome and multiple adverse ef)20 (fects when galantamine)]TJ
-0.02499 Tc 0.013 Tw T*
(was reintroduced.)Tj
-0.005 Tc 0.005 Tw 1 -1.23809 Td
(Galantamine is a reversible, competitive AChI and an)Tj
-0.02499 Tc 0.017 Tw -1 -1.2381 Td
(allosteric modulator of nicotinic acetylcholine receptors. In)Tj
0 Tc 0.013 Tw T*
(our case, at least 2 mechanisms of clinical deterioration)Tj
0.17 Tw 0 -1.2381 TD
(warrant discussion. First, galantamine discontinuation)Tj
0.011 Tw T*
(could lead to a withdrawal syndrome similar to that ob-)Tj
0 Tw 0 -1.23809 TD
(served with donepezil.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 412.6833 464.1197 Tm
(12)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 421.3043 460.8197 Tm
[(W)41 (ithin 2 weeks of galantamine)]TJ
-0.013 Tc 0.013 Tw -9.8385 -1.23809 Td
(discontinuation, our patient\325)Tj
-0.01289 Tc 10.90105 0 Td
(s)Tj
-0.013 Tc 0.62598 0 Td
(condition deteriorated, with)Tj
-0.01801 Tc 0.01801 Tw -11.52703 -1.2381 Td
(obvious cognitive, functional, and behavioral decline, and)Tj
0 Tc 0.22501 Tw T*
(therefore, the medication was resumed. Since galan-)Tj
-0.021 Tc 0 Tw T*
(tamine\325)Tj
-0.0211 Tc 2.85154 0 Td
(s)Tj
-0.021 Tc 0.021 Tw 0.61779 0 Td
(half-life is about 6 hours,)Tj
ET
BT
/T1_2 1 Tf
-0.019 Tc 0 Tw 6 0 0 6 455.185 412.1197 Tm
(13)Tj
ET
BT
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 463.5576 408.8197 Tm
(complete galantamine)Tj
0 Tc -13.86263 -1.2381 Td
(elimination \(5 half-lives\) will require approximately 30)Tj
-0.021 Tc 0.02 Tw T*
[(hours, when the ef)20 (fects of sudden withdrawal may appear)55 (.)]TJ
-0.02499 Tc 0.013 Tw T*
(Abrupt discontinuation of AChIs should be avoided. )Tj
-0.017 Tc 0.017 Tw 1 -1.2381 Td
(Second, when galantamine was restarted in our patient,)Tj
-0.01801 Tc 0.01801 Tw -1 -1.23809 Td
[(symptoms and signs of choliner)21.1 (gic excess \(\322toxicity\323\) de)]TJ
0 Tc 21.95295 0 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -21.95295 -1.2381 Td
(veloped. These manifested as nausea, vomiting, diarrhea,)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(280)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0.013 Tw 8 0 0 8 60 749.5293 Tm
(AA Fisher and MW Davis)Tj
ET
0 0 0 0 k
60.5 48.5 491 238.998 re
f
0 0 0 1 K
0.5 w 
60.5 270.791 m
551.5 270.791 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 9 0 0 9 118.3628 276.5409 Tm
(T)Tj
-0.02499 Tc 0.011 Tw 0.51185 0.00001 Td
(able 2.)Tj
ET
BT
/T1_6 1 Tf
9 0 0 9 151.8784 276.5409 Tm
[(Main Adverse Ef)19.3 (fects Reported to Australian Adverse Drug Reactions Advisory Committee)]TJ
ET
228.5 256.291 m
303.5 256.291 l
S
BT
/T1_1 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 242.2613 260.5409 Tm
(Galantamine)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 287.265 263.2909 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
7.5 0 0 7.5 364.7903 260.5409 Tm
(Donepezil)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 400.2047 263.2909 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
7.5 0 0 7.5 476.7762 260.5409 Tm
(Rivastigmine)Tj
ET
BT
/T1_1 1 Tf
5 0 0 5 523.4443 263.2909 Tm
(a)Tj
ET
345.5 256.291 m
422.5 256.291 l
S
60.5 242.291 m
551.5 242.291 l
S
BT
/T1_1 1 Tf
-0.01401 Tw 7.5 0 0 7.5 90.8748 246.5409 Tm
(Adverse Effect)Tj
19.03599 0 Td
(A)Tj
7.645 0 Td
(B)Tj
8.053 0 Td
(A)Tj
7.54299 0 Td
(B)Tj
8.358 0 Td
(A)Tj
7.442 0 Td
(B)Tj
ET
465.5 255.291 m
540.5 255.291 l
S
BT
/T1_6 1 Tf
0 Tw 7.5 0 0 7.5 63.5 230.5409 Tm
(Bradycardia)Tj
22.63277 0.00001 Td
(13 )Tj
7.21132 0.00001 Td
(6.12)Tj
5.76401 Tw 8.6302 0.00001 Td
[(26 2.21)-6923 (6)-6172 (4.02)]TJ
0 Tw -38.47429 -1.33336 Td
(Syncope)Tj
23.203 0 Td
(8)Tj
6.642 0 Td
(3.76)Tj
8.644 0 Td
(15)Tj
7.141 0 Td
(1.27)Tj
8.868 0 Td
(8)Tj
6.728 0 Td
(5.37)Tj
5.82201 Tw -61.226 -1.33333 Td
[(Dizziness)-18355 (10 4.71)-7255 (7)-6028 (0.59)-6923 (7)-6171 (4.69)]TJ
0 -1.33334 TD
[(Confusion/delirium/agitation)-10298 (18 8.47)-6698 (56)-6029 (4.77)-6367 (21)-5616 (14.09)]TJ
0 Tw T*
[(Arrhythmia)-18370 (5)-6085 (2.35)-7255 (8)-6028 (0.68)-6923 (2)-6172 (1.34)]TJ
-0.01401 Tw 0 -1.33333 TD
(Bundle branch block)Tj
0 Tw 23.20257 0.00001 Td
[(1)-6086 (0.47)-7254 (1)-6028 (0.08)]TJ
-0.01401 Tw -23.20257 -1.33334 Td
[(Atrioventricular block)-29780 (6)-6028 (0.51)]TJ
0 -1.33334 TD
[(Hypotension/circulatory collapse )-8617 (6)-6086 (2.82)-7255 (5)-6028 (0.42)-6922 (2)-6172 (1.34)]TJ
0 -1.33333 TD
(Myocardial infarct/cardiac arrest)Tj
23.20257 0.00001 Td
(1)Tj
0 Tw 6.64152 0.00001 Td
(0.47)Tj
9.2 0.00001 Td
(7)Tj
6.58408 0.00001 Td
(0.59)Tj
8.86831 0.00001 Td
[(1)-6172 (0.67)]TJ
-54.49648 -1.33338 Td
(Nausea)Tj
22.64667 0.00001 Td
(12)Tj
7.19743 0.00001 Td
[(5.65)-6699 (25)-6028 (2.13)-6367 (17)-5690 (1)74 (1.41)]TJ
-29.84409 -1.33335 Td
[(V)55 (omiting)-19369 (7)-6085 (3.29)-6699 (25)-6028 (2.13)-6441 (1)74 (1)-6172 (7.38)]TJ
T*
[(Diarrhea)-19370 (8)-6085 (3.76)-6699 (15)-6028 (1.27)-6923 (5)-6172 (3.35 )]TJ
-0.01401 Tw 0 -1.33334 TD
[(Fatal outcome)-16882 (5)-6086 (2.35)-6772 (1)74 (1)-6028 (0.93)-6923 (3)-6172 (2.01)]TJ
T*
[(Sudden death)-16991 (3)-6085 (1.41)-7255 (6)-6028 (0.51)-6923 (0)]TJ
0 -1.33333 TD
[(T)111 (otal number of reports)-12001 (1)74 (1)74 (1)-5530 (52.28)-6143 (304)-5472 (25.9)-6923 (85)-5616 (57.06)]TJ
ET
60.5 74.291 m
551.5 74.291 l
S
BT
/T1_6 1 Tf
7.5 0 0 7.5 63.5 80.5409 Tm
(PBS prescription \(to May 2007\))Tj
25.11497 0 Td
(212,309)Tj
15.384 0 Td
(1,173,553)Tj
16.218 0 Td
(148,958)Tj
-56.71697 -2.26666 Td
(PBS = Pharmaceutical Benefits Scheme.)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 63.5 57.2909 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 66.2795 54.5409 Tm
[(A)-264 (=)]TJ
0 Tc -0.01401 Tw 1.77875 0 Td
(absolute number of reported cases; B = number of reported cases per 100,\000 prescriptions.)Tj
ET
60.25 48.25 491.5 239.498 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
76 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
77 0 obj
<</OP false/OPM 0/op false>>
endobj
96 0 obj
<</A 97 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
97 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
70 0 obj
[98 0 R]
endobj
71 0 obj
<</Length 12497>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.006 Tw 10.5 0 0 10.5 60 730.8196 Tm
(facial trauma, and lacerations to his forehead, nose, and)Tj
-0.00101 Tc 0.00101 Tw 0 -1.23809 TD
[(right elbow following a fall. W)40 (itnesses reported that the)]TJ
-0.022 Tc 0.022 Tw 0 -1.2381 TD
(man had loss of consciousness. He was nauseated and had)Tj
-0.008 Tc 0.008 Tw T*
(vomited the previous day and developed weakness, diar-)Tj
-0.002 Tc 0.00101 Tw 0 -1.23809 TD
(rhea, and dizziness. He fell getting out of the bed on the)Tj
0 Tc 0.062 Tw 0 -1.2381 TD
[(admission day)65 (. Three weeks prior to admission he was)]TJ
0.04401 Tw T*
(restarted on galantamine prolonged release 8 mg in the)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(mor)-25 (ning after being of)20 (f the drug for 2 weeks.)]TJ
-0.015 Tc 0.01401 Tw 1 -1.2381 Td
[(About 1.5 years earlier)40 (, the patient was diagnosed with)]TJ
-0.03999 Tc 0.019 Tw -1 -1.2381 Td
[(m)-15 (i)-15 (l)-15 (d)-15 ( )-15 (d)-15 (e)-15 (m)-15 (e)-15 (n)-15 (t)-15 (i)-15 (a)-15 ( )-15 (of mixed etiology \(Alzheimer)-35 (\325)55 (s and vascular\))]TJ
-0.03799 Tc 0.02299 Tw T*
(and was treated with galantamine 8 mg daily with satisfacto-)Tj
-0.03 Tc 0.015 Tw 0 -1.2381 TD
(ry stabilization for the first 3 months and slow worsening in)Tj
-0.035 Tc 0.02 Tw 0 -1.23809 TD
[(the next year)55 (. He scored 26 of 30 on the Folstein Mini-Men-)]TJ
-0.015 Tc 0.011 Tw 0 -1.2381 TD
(tal State Examination \(MMSE\) before and 3 months after)Tj
-0.036 Tc 0.021 Tw T*
[(therapy started and 23 nine months later)55 (. Three months prior)]TJ
-0.035 Tc 0.02 Tw 0 -1.23809 TD
(to the current admission he had a syncopal episode with low)Tj
-0.02699 Tc 0.01199 Tw 0 -1.2381 TD
(blood pressure \(100/80 mm Hg\) but without orthostatic hy)Tj
0 Tc 21.9531 0.00001 Td
(-)Tj
-0.03999 Tc 0.00101 Tw -21.9531 -1.2381 Td
(potension. An electrocardiogram \(ECG\) showed sinus brady-)Tj
-0.015 Tc 0 Tw 0 -1.23809 TD
[(cardia of 59 beats/min, with nor)-25 (mal PR and QT)70 (c intervals)]TJ
-0.02299 Tc 0 -1.2381 TD
(\(T)Tj
0.007 Tw 0.82869 0 Td
(able 1)Tj
ET
BT
/T1_1 1 Tf
-0.021 Tc 0 Tw 6 0 0 6 92.7295 487.1197 Tm
(9,10)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.007 Tw 10.5 0 0 10.5 102.6914 483.8197 Tm
(\). He was hospitalized, but the cause of syncope)Tj
-0.02699 Tc 0.01199 Tw -4.06585 -1.2381 Td
[(was not identified. T)70 (wo months later)40 (, at a routine check-up,)]TJ
-0.019 Tc 0.004 Tw 0 -1.23809 TD
(galantamine was discontinued by his physician because of)Tj
-0.03999 Tc 0.01601 Tw T*
[(the syncopal episode. W)42.4 (ithin 2 weeks of galantamine discon)]TJ
0 Tc 21.95293 0 Td
(-)Tj
-0.036 Tc 0.021 Tw -21.95293 -1.2381 Td
(tinuation, family members noted worsening in cognitive, be-)Tj
-0.033 Tc 0.01801 Tw T*
(havioral, and functional status. Galantamine was restarted at)Tj
-0.03999 Tc 0.013 Tw T*
(the same dose \(8 mg daily\).)Tj
-0.02299 Tc 0.02299 Tw 1 -1.2381 Td
(The patient had a history of coronary artery disease, hy-)Tj
-0.02499 Tc 0.01199 Tw -1 -1.23809 Td
(pertension, hypercholesterolemia, osteoarthritis, hiatus her)Tj
0 Tc 21.95294 0 Td
(-)Tj
-0.011 Tc 0.011 Tw -21.95294 -1.2381 Td
[(nia, and sur)20.4 (gical treatment for benign prostatomegaly)67.7 (.)]TJ
0 Tw 21.29671 0 Td
(At)Tj
-0.005 Tc 0.005 Tw -21.29671 -1.2381 Td
(the time of presentation, he was also receiving, for more)Tj
0 Tc 0.024 Tw T*
[(than 3 years, irbesartan 75 mg daily)65 (, clopidogrel 75 mg)]TJ
-0.011 Tc 0 Tw T*
(daily)Tj
-0.0114 Tc 1.8779 0 Td
(,)Tj
-0.011 Tc 0.011 Tw 0.48855 0 Td
[(simvastatin 20 mg daily)65 (, pantoprazole 40 mg daily)65 (,)]TJ
-0.00101 Tc 0.00101 Tw -2.36645 -1.2381 Td
[(e)1 (r)21 (gocalciferol 1000 IU daily)65 (, calcium carbonate 600 mg)]TJ
-0.02499 Tc 0.013 Tw T*
[(twice a day)65 (, and acetaminophen 1 g 2 times a day)65 (.)]TJ
-0.022 Tc 0.022 Tw 1 -1.23809 Td
(On admission, the patient was confused, restless, agitat-)Tj
-0.02499 Tc 0.015 Tw -1 -1.2381 Td
[(e)-10 (d)-10 (,)-10 ( )-10 (a)-10 (n)-10 (d)-10 ( )-10 (i)-10 (n)-10 (c)-10 (o)-10 (n)-10 (t)-10 (i)-10 (n)-10 (e)-10 (n)-10 (t)-10 ( )-10 (o)-10 (f)-250 (urine. His blood pressure was 84/46)]TJ
-0.035 Tc 0.005 Tw 24.57143 43.33333 Td
[(mm)-200 (Hg, pulse 79 beats/min, respiratory rate 18 breaths/ min,)]TJ
-0.022 Tc 0.01199 Tw T*
(temperature 36.5)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 11.5 0 0 11.5 387.6173 716.3197 Tm
(\373)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.01199 Tw 10.5 0 0 10.5 391.1879 717.8197 Tm
(C, and room-air oxygen saturation 95%.)Tj
-0.024 Tc 0.01401 Tw -6.97027 -1.2381 Td
(He had deep lacerations of his forehead, nose, and right el-)Tj
-0.00999 Tc 0.03799 Tw 0 -1.2381 TD
(bow and loose front upper teeth, but no focal neurologic)Tj
0.06799 Tw 0 -1.23809 TD
[(deficit. Complete blood cell count biochemistry)65 (, thyroid)]TJ
0.039 Tw 0 -1.2381 TD
(function, cardiac troponin I, and C-reactive protein were)Tj
-0.035 Tc 0.013 Tw T*
[(nor)-25 (mal. No blood, urinary)65 (, or fecal infection was detected.)]TJ
-0.02499 Tc 0.02499 Tw 1 -1.23809 Td
[(The QT)70 (c interval was significantly prolonged regardless)]TJ
-0.01401 Tc 0.013 Tw -1 -1.2381 Td
[(of the for)-25 (mula applied \(T)70 (able 1\). Electrocardiographic 24)]TJ
-0.013 Tc T*
(hour Holter recording on the third admission day showed)Tj
-0.009 Tc 0.009 Tw 0 -1.23809 TD
(sinus rhythm with average heart rate 60 beats/min \(mini-)Tj
0 Tc 0.01199 Tw 0 -1.2381 TD
(mum 40, maximum 90\), frequent multifocal ventricular)Tj
-0.032 Tc 0.017 Tw 0 -1.23809 TD
[(e)-15 (c)-15 (t)-15 (o)-15 (pics, runs of ventricular beats, ventricular bigeminy and)]TJ
-0.03799 Tc 0.02299 Tw 0 -1.2381 TD
[(trigeminy)65 (, frequent supraventricular ectopics, aberrantly con-)]TJ
-0.015 Tc 0.08299 Tw T*
(ducted supraventricular run of 10 beats, supraventricular)Tj
-0.039 Tc 0.024 Tw 0 -1.23809 TD
[(bigeminy and trigeminy)65 (, supraventricular tachycardia, but no)]TJ
-0.015 Tc 0.08299 Tw 0 -1.2381 TD
[(pauses. Echocardiogram revealed nor)-22.7 (mal left ventricular)]TJ
-0.03999 Tc 0.004 Tw 0 -1.23809 TD
(size, mild segmental left ventricular dysfunction, and estimat-)Tj
0.013 Tw T*
(ed left ventricular ejection fraction of 51%. )Tj
-0.007 Tc 0.007 Tw 1 -1.2381 Td
(Computed tomography \(CT\) of the head did not show)Tj
0 Tc 0.082 Tw -1 -1.2381 Td
(any evidence of acute intracranial bleed or infarct, but)Tj
-0.00999 Tc 0.00999 Tw T*
(there was prominence of cerebral sulci and the ventricles)Tj
-0.017 Tc 0.017 Tw T*
(in keeping with cerebral atrophy)Tj
-0.0168 Tc 12.46004 0 Td
(,)Tj
-0.017 Tc 0.48308 0 Td
(and there were old lacu)Tj
0 Tc 9.00986 0 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -21.95298 -1.2381 Td
(nar infarcts. CT of the cervical spine revealed fractures of)Tj
-0.015 Tc 0.015 Tw T*
(the spinous process of C4, right superior articular process)Tj
-0.007 Tc 0.007 Tw T*
(of C3, and left superior articular process of C5. Findings)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(from chest and abdominal X-rays were unremarkable.)Tj
0 Tc 0.19299 Tw 1 -1.23809 Td
(Galantamine and irbesartan were ceased. No other)Tj
-0.02499 Tc 0.024 Tw -1 -1.23809 Td
(changes in the patient\325)Tj
-0.0251 Tc 8.46684 0 Td
(s)Tj
-0.02499 Tc 0 Tw 0.61314 0 Td
(long-ter)Tj
-0.0251 Tc 2.99008 0 Td
(m)Tj
-0.02499 Tc 0.024 Tw 1.00216 0 Td
(medications were made.)Tj
-0.00999 Tc 0.00999 Tw -13.07222 -1.2381 Td
[(The patient was treated with a cervical collar)40 (, infusion of)]TJ
0 Tc 0.20599 Tw 0 -1.23809 TD
(NaCl 0.9% \(1.5 L/day\), prophylactic antibiotics, and)Tj
-0.007 Tc 0.006 Tw T*
(thromboembolic prophylaxis \(enoxaparin sodium 40 mg)Tj
-0.008 Tc 0.008 Tw 0 -1.2381 TD
(daily\). Lacerations were sutured and loose teeth were re-)Tj
-0.022 Tc 0.022 Tw 0 -1.23809 TD
(moved. His delirium resolved over 6 days, but he required)Tj
-0.024 Tc 0.024 Tw T*
(haloperidol for agitation \(0.25 mg intravenously 6 times in)Tj
-0.00011 Tc 0 -1.2381 TD
(6)Tj
0 Tc 0.13901 Tw 0.88904 0 Td
[(days\). The QT)70 (c interval shortened to 443 msec \(by)]TJ
ET
0 0 0 0 k
318 745 234 10 re
f
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2008 February)55 (, V)110 (olume 42    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(279)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.5 48.5 491 181.582 re
f
0 0 0 1 K
0.5 w 
60.5 212.583 m
551.5 212.583 l
S
BT
0 0 0 1 k
/T1_4 1 Tf
0.011 Tw 9 0 0 9 84.5996 218.3328 Tm
[(T)74 (able 1.)]TJ
ET
BT
/T1_5 1 Tf
9 0 0 9 118.1152 218.3328 Tm
[(Electrocardiographic Characteristics and Corrected QT Intervals Calculat\ed by Dif)18 (ferent Correction Formulas)]TJ
ET
342.5 198.083 m
549.5 198.083 l
S
BT
/T1_4 1 Tf
0 Tc -0.01401 Tw 7.5 0 0 7.5 153.7645 196.3327 Tm
[(Heart Rate, )-3408 (PR,)-3970 (RR,)-4093 (QT)110 (,)]TJ
33.50779 0.80002 Td
[(QT)74 (c, msec, by formula)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 484.6291 205.0828 Tm
(a)Tj
ET
60.5 184.083 m
551.5 184.083 l
S
BT
/T1_4 1 Tf
7.5 0 0 7.5 88.9105 188.3328 Tm
(Date)Tj
8.946 0 Td
[(beats/min)-3526 (msec)-3108 (msec)-3175 (msec)-3159 (Bazett)-3274 (Fridericia)-3473 (Framingham)-2984 (Hodges)]TJ
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.5 172.3328 Tm
(Feb 6, 2007)Tj
13.28898 0 Td
(59)Tj
7.529 0 Td
[(146)-3692 (1017)-3933 (425)-4332 (421)]TJ
24.66399 0 Td
(423)Tj
8.263 0 Td
(422)Tj
7.79099 0 Td
(423)Tj
-61.53598 -1.33333 Td
(May 14, 2007)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 108.7238 165.0828 Tm
(b)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 163.1614 162.3328 Tm
(83)Tj
7.52797 0.00001 Td
[(168)-4249 (723)-3932 (428)-4332 (503)-5479 (477)-6595 (471)-6124 (468)]TJ
-0.01401 Tw -20.81616 -1.33334 Td
[(May 18, 2007)-7258 (54)-6417 (144)-3914 (1)74 (1)74 (1)74 (1)-3932 (468)-4333 (443)-5478 (452)-6595 (451)-6124 (457)]TJ
0 -1.33334 TD
[(May 19, 2007)-7258 (63)-6417 (128)-4248 (952)-3933 (420)-4332 (430)-5479 (427)-6595 (427)-6123 (425)]TJ
0 -1.33333 TD
(May 22, 2007)Tj
0 Tw 13.28819 0.00001 Td
(55)Tj
7.52797 0.00001 Td
[(136)-3692.2 (1091)-3931.9 (456)-4332 (436)]TJ
24.66312 0.00003 Td
(443)Tj
8.263 0 Td
(442)Tj
7.791 0 Td
(447)Tj
-0.01401 Tw -61.53328 -1.33338 Td
(May 24, 2007)Tj
0 Tw 13.28819 0.00001 Td
(59)Tj
7.52797 0.00001 Td
[(136)-3693 (1017)-3932 (444)-4332 (440)]TJ
24.664 0 Td
(441)Tj
8.263 0 Td
(441)Tj
7.792 0 Td
(442)Tj
-0.01401 Tw -61.53516 -1.33335 Td
(Upper normal limit)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 124.1138 115.0828 Tm
(9)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 350.9921 112.3328 Tm
(483)Tj
7.147 0 Td
(460)Tj
8.263 0 Td
(457)Tj
7.791 0 Td
(457)Tj
ET
60.5 96.083 m
551.5 96.083 l
S
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.5 102.3328 Tm
(Upper normal limit)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 124.1138 105.0828 Tm
(10)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 350.9921 102.3328 Tm
(457)Tj
7.14618 0.00001 Td
(445)Tj
-0.01401 Tw -45.47845 -2.40001 Td
(ECG = electrocardiogram. )Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 63.5 77.0828 Tm
(a)Tj
ET
BT
/T1_5 1 Tf
0.048 Tc -0.034 Tw 7.5 0 0 7.5 66.25 74.3328 Tm
[(Bazett: QT)111 (c = QT/\(RR)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 145.8564 77.0828 Tm
(1/2)Tj
ET
BT
/T1_5 1 Tf
-0.034 Tw 7.5 0 0 7.5 153.5297 74.3328 Tm
[(\); Fridericia: QT)111 (c = QT/\(RR)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 251.6442 77.0828 Tm
(1/3)Tj
ET
BT
/T1_5 1 Tf
-0.034 Tw 7.5 0 0 7.5 259.3176 74.3328 Tm
[(\); Framingham: QT)111 (c = QT + 0.154 \(1 \320 RR\); Hodges: QT)110 (c = QT + 105 \()]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 514.1443 77.0828 Tm
(1)Tj
ET
BT
/T1_5 1 Tf
0.048 Tc 7.5 0 0 7.5 517.1656 74.3328 Tm
(/RR\3211\).)Tj
0 Tc -0.01401 Tw -60.12208 -1.2 Td
[(Upper normal limits of QT)111 (c interval were determined by Luo et al.,)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 282.6186 68.0828 Tm
(9)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 287.3777 65.3328 Tm
(using 10,303 normal ECGs, and by Mason et al.,)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 448.2501 68.0828 Tm
(10)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 455.7888 65.3328 Tm
(using 46,129 normal ECGs.)Tj
ET
BT
/T1_4 1 Tf
0 Tw 5 0 0 5 63.5 58.0828 Tm
(b)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 66.5542 55.3328 Tm
(Day of hospital admission.)Tj
ET
60.25 48.25 491.5 182.082 re
h
S
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tw 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
72 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
73 0 obj
<</OP false/OPM 0/op false>>
endobj
98 0 obj
<</A 99 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
99 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
65 0 obj
[100 0 R]
endobj
66 0 obj
<</Length 10666>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 18.25 391 13 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 10 0 0 10 60 24.4116 Tm
(278)Tj
ET
BT
/T1_1 1 Tf
0 Tc 5 0 0 5 83.7499 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 96.931 24.4116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 230.0559 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.237 24.4116 Tm
[(2008 February)55 (, V)110 (olume 42)]TJ
ET
0 0 0 0 k
472 18 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 10 0 0 10 475.7004 24.1616 Tm
[(www)75 (.theannals.com)]TJ
ET
0 0 0 1 K
2 w 
225.299 709.926 m
373.096 709.926 l
S
BT
/T1_3 1 Tf
0.075 Tc 0.011 Tw 18 0 0 18 238.4009 712.5727 Tm
[(C)-25 (ASE REPOR)90 (TS)]TJ
ET
0.001 708.829 234.6 16.046 re
f
0 0 0 0 k
60 38.659 492 479.282 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tc 0 Tw 27.357 0 0 27.357 59.7366 497.7603 Tm
(A)Tj
ET
BT
/T1_5 1 Tf
-0.039 Tc 0.024 Tw 10.5 0 0 10.5 77.875 510.7603 Tm
(cetylcholinesterase inhibitors \(AChIs\))Tj
-0.03999 Tc 0.019 Tw 0 -1.2381 TD
[(a)-15 (r)-15 (e)-15 ( )-15 (u)-15 (s)-15 (ed in treatment of mild-to-mod-)]TJ
-0.021 Tc 0.006 Tw -1.70238 -1.23809 Td
[(erate Alzheimer)-35 (\325)56 (s disease.)]TJ
ET
BT
/T1_0 1 Tf
-0.02 Tc 0 Tw 6 0 0 6 164.5682 488.0604 Tm
(1,2)Tj
ET
BT
/T1_5 1 Tf
-0.021 Tc 0.006 Tw 10.5 0 0 10.5 174.152 484.7603 Tm
(These drugs)Tj
-0.015 Tc 0.092 Tw -10.87162 -1.23809 Td
(also improve cognition in patients with)Tj
-0.01601 Tc 0.00101 Tw T*
(other types of dementia, as well as those)Tj
-0.02699 Tc 0.01199 Tw 0 -1.23809 TD
(with schizophrenia, and may have neuro)Tj
0 Tc 15.1911 0 Td
(-)Tj
-0.034 Tc 0.019 Tw -15.1911 -1.2381 Td
(protective properties.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 141.4777 436.0604 Tm
(3)Tj
ET
BT
/T1_5 1 Tf
-0.03439 Tc 10.5 0 0 10.5 146.7392 432.7603 Tm
(A)Tj
-0.034 Tc 0.019 Tw 0.92248 0 Td
(Cochrane review)Tj
-0.015 Tc 0.302 Tw -9.18336 -1.2381 Td
[(concluded that there is no dif)20 (ference)]TJ
-0.03999 Tc 0.013 Tw T*
[(among AChIs with respect to ef)20 (ficacy)65 (.)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 206.3149 410.0604 Tm
(1)Tj
ET
BT
/T1_5 1 Tf
0.127 Tw 10.5 0 0 10.5 70.5 393.7603 Tm
(AChIs are well tolerated.)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 180.0401 397.0604 Tm
(1,4)Tj
ET
BT
/T1_5 1 Tf
0 Tc 10.5 0 0 10.5 191.5024 393.7603 Tm
(Among)Tj
-0.022 Tc 0.022 Tw -12.52404 -1.2381 Td
[(choliner)20 (gically mediated adverse ef)20 (fects,)]TJ
-0.02499 Tc 0.02499 Tw T*
(gastrointestinal symptoms \(nausea, vom-)Tj
0 Tc 0.048 Tw T*
(iting, diarrhea, anorexia\) predominate.)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
(Patients receiving AChIs rarely develop)Tj
0 Tc 0.186 Tw 0 -1.23809 TD
[(potentially serious cardiovascular ad)3 (-)]TJ
-0.015 Tc 0.015 Tw T*
[(verse ef)19.3 (fects such as syncope, bradycar)]TJ
0 Tc 15.19097 0.00002 Td
(-)Tj
-0.024 Tc 0.024 Tw -15.19097 -1.23811 Td
(dia, atrial arrhythmias, and sinoatrial and)Tj
-0.00999 Tc 0.00999 Tw T*
(atrioventricular block.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 150.9171 293.0603 Tm
(5)Tj
ET
BT
/T1_5 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 156.4806 289.7603 Tm
(Seventeen cases)Tj
-0.01401 Tc 0.01401 Tw -9.18863 -1.2381 Td
(of cardiac dysrhythmias associated with)Tj
-0.009 Tc 0.009 Tw T*
(donepezil have been reported.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 183.384 267.0604 Tm
(6)Tj
ET
BT
/T1_5 1 Tf
-0.009 Tc 0.009 Tw 10.5 0 0 10.5 188.9529 263.7603 Tm
[(T)71 (wo pa-)]TJ
-0.006 Tc 0.006 Tw -12.28123 -1.2381 Td
(tients, one on galantamine)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 168.7279 254.0604 Tm
(7)Tj
ET
BT
/T1_5 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 174.3159 250.7603 Tm
(and another)Tj
0 Tc 0.02499 Tw -10.88723 -1.2381 Td
(on rivastigmine,)Tj
ET
BT
/T1_0 1 Tf
0 Tw 6 0 0 6 128.4997 241.0604 Tm
(8)Tj
ET
BT
/T1_5 1 Tf
0.02499 Tw 10.5 0 0 10.5 134.3897 237.7603 Tm
(developed prolonged)Tj
-0.021 Tc 0.021 Tw -7.08473 -1.23809 Td
(cardiac repolarization \(prolonged QT in)Tj
0 Tc 15.191 0.00001 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -15.191 -1.2381 Td
(terval\), which may lead to life-threaten)Tj
0 Tc 15.19106 0.00001 Td
(-)Tj
-0.021 Tc 0.021 Tw -15.19106 -1.2381 Td
(ing polymorphic ventricular arrhythmias)Tj
-0.02499 Tc 0.013 Tw T*
(\(torsade de pointes\).)Tj
-0.03 Tc 0.019 Tw 1 -1.2381 Td
[(W)80 (e report a case in which galantamine)]TJ
-0.01401 Tc 0.004 Tw -1 -1.2381 Td
(was associated with QT interval prolon-)Tj
-0.019 Tc 0.009 Tw T*
(gation, syncope, delirium, vomiting, and)Tj
0 Tc 0.244 Tw 0 -1.2381 TD
[(d)10 (i)10 (a)10 (r)10 (r)10 (hea. W)80 (e also searched the Aus-)]TJ
-0.021 Tc 0.021 Tw T*
(tralian Adverse Drug Reaction Advisory)Tj
-0.024 Tc 0.024 Tw 0 -1.23809 TD
(Committee \(ADRAC\) database for simi-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
[(lar ef)21.5 (fects related to AChIs.)]TJ
ET
BT
/T1_6 1 Tf
0.011 Tw 10.5 0 0 10.5 318 94.3901 Tm
(Case Report)Tj
ET
BT
/T1_5 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 328.5 73.3902 Tm
(An 85)Tj
0 Tw 2.4733 0.00001 Td
(-year)Tj
0 Tc 2.00379 0.00001 Td
(-)Tj
-0.006 Tc 0.006 Tw 0.40183 0.00001 Td
(old white man, who was a widower and a)Tj
0 Tc 0.017 Tw -5.87891 -1.23811 Td
(resident of an assisted living facility was brought to the)Tj
-0.024 Tc 0.024 Tw T*
[(emer)20 (gency department by ambulance because of agitation,)]TJ
ET
0 0 0 0 k
60 566.941 492 85 re
f
BT
0 0 0 1 k
/T1_7 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 623.0804 Tm
[(Pr)25 (olong)15 (ed QT Inter)-30 (val, Syncope)-20 (, and Delirium with Galantamine)]TJ
ET
BT
/T1_4 1 Tf
10.5 0 0 10 60 587.0804 Tm
(Alexander A Fisher and Michael W Davis)Tj
ET
0.5 w 
60 60.25 m
294 60.25 l
S
BT
/T1_4 1 Tf
8.5 0 0 8.5 60 48 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 118.042 313 399.899 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 501.2782 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 288.4204 501.2782 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.00101 Tw 8.5 0 0 8.5 293.6549 501.2782 Tm
[(T)111 (o describe a case of QT interval prolongation, syncope, and delirium)]TJ
0 Tc 0.22701 Tw -5.01822 -1.29411 Td
(associated with galantamine use and to analyze similar cases related to)Tj
-0.013 Tc 0.013 Tw 0 -1.29412 TD
(acetylcholinesterase inhibitors \(AChIs\) reported to the Australian Adv\erse Drug)Tj
-0.02499 Tc 0.011 Tw T*
(Reaction Advisory Committee \(ADRAC\).)Tj
ET
BT
/T1_6 1 Tf
-0.02 Tc 0 Tw 7 0 0 7 251 454.2783 Tm
[(CASE)-397 (SUMMAR)37 (Y)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 307.0682 454.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.01401 Tc 0.01401 Tw 8.5 0 0 8.5 312.6178 454.2783 Tm
(An 85-year-old man with dementia was treated with prolonged)Tj
-0.013 Tc 0.013 Tw -7.24915 -1.29412 Td
(release galantamine 8 mg daily for 1.5 years. Three months prior to the \current)Tj
-0.022 Tc 0.022 Tw T*
(admission, he had a syncopal episode with low blood pressure and bradyca\rdia.)Tj
0 Tc T*
(T)Tj
0.065 Tw 0.55591 0 Td
(wo months later)Tj
-0.00011 Tc 7.13146 0 Td
(,)Tj
0 Tc 0.62088 0 Td
(galantamine was withdrawn, but within 2 weeks, the man)Tj
0.261 Tw -8.30825 -1.29413 Td
(developed marked cognitive, behavioral, and functional deterioration and\)Tj
-0.01601 Tc 0.01601 Tw T*
[(galantamine was restarted. Three weeks later)55 (, he developed syncope, delirium,)]TJ
0 Tc 0.067 Tw T*
(hypotension, and prolonged QT interval with serious cardiac arrhythmias,\ in)Tj
-0.017 Tc 0.017 Tw T*
(addition to vomiting and diarrhea. A complete blood cell count and bioch\emistry)Tj
0 Tc 0.27699 Tw T*
(panel performed on admission were normal. No infection was detected.)Tj
-0.015 Tc 0.015 Tw T*
(Galantamine and irbesartan were ceased. The delirium fully resolved in 6\ days,)Tj
0 Tc 0.075 Tw T*
[(and the QT interval shortened from 503 to 443 msec \(corrected by Bazett\\325)18 (s)]TJ
-0.02499 Tc 0.011 Tw T*
(formula\) 4 days after discontinuation of galantamine and remained norma\l. )Tj
ET
BT
/T1_6 1 Tf
-0.02299 Tc 0 Tw 7 0 0 7 251 319.2783 Tm
(DISCUSSION)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.9467 319.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.03101 Tc 0.01601 Tw 8.5 0 0 8.5 298.4751 319.2783 Tm
[(I)-15 (n the ADRAC reports, galantamine was associated with 18 cases of)]TJ
-0.015 Tc 0.104 Tw -5.58531 -1.29412 Td
(delirium/confusion, 8 of syncope, 13 of bradycardia, 6 of other arrhythm\ias or)Tj
-0.037 Tc 0.022 Tw T*
(conduction abnormalities, and 6 of hypotension. Donepezil was associated\ with 56,)Tj
-0.015 Tc 0.011 Tw T*
[(15, 26, 15, and 5, and rivastigmine with 21, 8, 6, 2, and 2, respectivel\y)74 (, of these)]TJ
-0.019 Tc 0.004 Tw 0 -1.29411 TD
(reactions. Five fatal outcomes were reported in association with galanta\mine, 1)Tj
0 Tc 33.44433 0.00001 Td
(1)Tj
-0.015 Tc 0.12199 Tw -33.44433 -1.29413 Td
(with donepezil, and 3 with rivastigmine, including 3, 6, and 0 sudden de\aths,)Tj
0 Tc 0.16499 Tw 0 -1.29412 TD
[(r)15 (e)15 (s)15 (p)15 (e)15 (c)15 (t)15 (i)15 (v)15 (ely)74 (. This case, along with previously published reports and cases)]TJ
-0.02 Tc 0.02 Tw T*
(identified from the ADRAC database, illustrates that AChIs may lead to d\elirium,)Tj
-0.017 Tc 0.017 Tw T*
(syncope, hypotension, and life-threatening arrhythmias. The Naranjo prob\ability)Tj
0 Tc 0.25999 Tw T*
(scale indicated that galantamine was the probable cause of QT interval)Tj
-0.02499 Tc 0.011 Tw T*
(prolongation, syncope, and delirium in this patient.)Tj
ET
BT
/T1_6 1 Tf
-0.03 Tc 0 Tw 7 0 0 7 251 195.2783 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 300.3924 195.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.021 Tc 0.021 Tw 8.5 0 0 8.5 305.8704 195.2783 Tm
(Administration of galantamine and other AChIs requires vigilance)Tj
0 Tc 0.02699 Tw -6.45534 -1.29412 Td
(and assessment of risk factors that may precipitate QT interval prolonga\tion,)Tj
-0.02499 Tc 0.011 Tw 0 -1.29411 TD
(syncope, and delirium.)Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 159.2783 Tm
[(KEY)-377 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.8581 159.2783 Tm
(:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 298.1792 159.2783 Tm
(delirium, galantamine, prolonged QT interval, syncope.)Tj
ET
BT
/T1_8 1 Tf
8.5 0 1.80673 8.5 251 144.2783 Tm
(Ann Pharmacother)Tj
ET
BT
/T1_4 1 Tf
0 Tw 8.5 0 0 8.5 322.581 144.2783 Tm
(2008;42:278-83.)Tj
0.011 Tw -8.42129 -1.76471 Td
(Published Online, 8 Jan 2008, )Tj
ET
BT
/T1_8 1 Tf
0 Tw 8.5 0 1.80673 8.5 360.8325 129.2783 Tm
[(www)55 (.theannals.com)]TJ
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 432.7881 129.2783 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1K514)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 299.75243 11 Tm
( at UNIV OF MICHIGAN on April 18, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
26 0 obj
<</BaseFont/LORKSW+GillSans/Encoding 23 0 R/FirstChar 32/FontDescriptor 25 0 R/LastChar 84/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 708 0 500 0 0 0 0 0 0 0 0 0 823 510 0 604 458 604]>>
endobj
42 0 obj
<</BaseFont/QESCJA+GillSans-Bold/Encoding 39 0 R/FirstChar 32/FontDescriptor 41 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 271 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 802 0 0 813 0 333 0 0 0 0 0 0 656 875 0 604 719 0 0 0 0 0 0 0 0 0 0 0 0 531 0 500 583 552 0 542 583 271 0 0 271 958 583 594 583 0 448 0 406 583 510 781 0 510]>>
endobj
46 0 obj
<</BaseFont/WZUNIQ+Helvetica-Oblique/Encoding 43 0 R/FirstChar 32/FontDescriptor 45 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
50 0 obj
<</BaseFont/QCENPR+Helvetica-Bold/Encoding 47 0 R/FirstChar 32/FontDescriptor 49 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
47 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
49 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 48 0 R/FontName/QCENPR+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
48 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  QCENPR+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      ²   €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      üwŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
43 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
45 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 44 0 R/FontName/WZUNIQ+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
44 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  WZUNIQ+Helvetica-Oblique   Eø øøøøû:ûtú|ú7
 ‹
 o
 ‹‹      ü  !¬  l €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~  Ã ı‰Â!sºëH†–«%œ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖüœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æü‹õâó÷Sõ#!ü@ vùawÎã÷/ùa3ıaû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
39 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 68/D 71/G 73/I 80/P/Q 83/S/T 97/a 99/c/d/e 103/g/h/i 108/l/m/n/o/p 114/r 116/t/u/v/w 121/y]/Type/Encoding>>
endobj
41 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 40 0 R/FontName/QESCJA+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
40 0 obj
<</Length 2332/Length1 2332/Subtype/Type1C>>stream
  QESCJA+GillSans-Bold   Aø øøøøûEûzú5
 ‹‹
 ‹‹       ;±  ö }‹”Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    1 S P M O H F E  2 5 * U W B  4 Z D Q % J V N X I (    E … Ì å'ğBœŸ3L‹° I¢Îk°é)˜Óü‘ v÷¦÷÷2÷Ş÷>÷M÷CŞù>ı>÷>÷¦÷÷1Ï÷ëèE÷û0ûûÇç¬vQXoo=<û^ v÷â÷‚wË÷%°÷eøaû%üa÷%÷[Ğà«­½À¢¤s±³÷aªr–n‹S[^+`‰S‚á÷Çá°÷/÷f÷/øÁ÷z÷Eû&Êûûû9û1û%÷,÷+ñ÷1Ã÷Kû/&gSGTX®÷ó¶¼ÊÔªO1ü vù>wÊ÷%÷dù>û%ı>÷%H vø	ã3ìÇ÷%÷A÷%Ø÷aøaû%üa÷%¸÷½Ä±¦¯´ªpJû­÷%÷¹÷+´CP^uV]û ûzá÷ÿ aÀ ÿ GaHÿ IáHÿ ›ıpì5á§÷û÷1÷÷÷%÷ò€ø¦øaû¦û:cûRñ@6Ñ[Æ‚‰p…R~Zj¤yª‚‰ô@%qvYdN¿B÷V÷)ê»ö¢„¯m©ñ@?ØûD]ÀÁ÷[İİò€¤¤œ®´¦„¡{§Íê€ûíBº¯°»½¬fa[fc]]e±¸ô@÷\ülcpK>a®­µ ÏÓ´yj)‚á÷×ğá°÷*÷_÷ø’÷#ZG^zQ0S»İ†÷ß÷<’ûêûû"&'û!û$ô-÷6¯â‹ÈŞûÔ÷{Ë‘°°ÄÃ±eL‘H‚ì3ã÷±ì÷hw®÷'÷Y÷%¼ø ù>û%û…dd•aû/)û!ûç%÷¼±˜¬´|f÷%¼û%÷pmr€lG`Ãßç¶ÀÔ¥­| ü÷uû1÷
øà÷"º÷CøD÷CùÏmEtû  A¶÷+¹ò÷‹÷+‹÷2û÷Rû•‹ûˆ‹û)ûG‹ûC‹ûM÷,û÷t÷7÷K÷‚÷÷üüø÷áß÷÷	îBûû,@ûû5Ş÷Ğ vøÁ÷÷§÷>ùHù>ı,û÷‹üÁ÷>øÁ÷‹ûÑ vù>wİ÷>÷ù>û>ı>÷>ûˆ‚ö÷œîÙ÷%øøaû<÷%yûUûloÍûZûŞ_ë¸±“ ¾ôwdo„m^q¨¸÷R÷<û —vøjwø÷k‚Ü÷højû.(û’)÷’û/û‚á÷¼ì¬÷'÷÷%ø§÷si€‰|‚”¢÷fğ<²ûBHxfOû
º¹Í©ÅÊŸi`ˆûUO:uûQÂTÕ½¹™±Ãf•¢|»²Ä£³ûtÚusn~pqv¡¦¹´Ÿáªü—vê÷½û=í•ÙãïÎbºP\hj]f›u®}‘[uTnq]‚÷øV÷¶÷C÷@÷Cøªù°5F›?û2%=û
û‰÷ï´‹ûchtJ@O¢Ì)û'hÏÆl÷÷,÷×÷÷‚ûïn‹ò­²¡ÈÅÆz_îû û\vù>wŒøø‘øaû,#û*÷û/÷Hüûû¼÷.û*‚ò÷—vªö³÷/øc÷sKlƒh8TÁİÜÃ¿â¯·€w±÷ [O—\û,û'û!û$ô-÷6¼¼• ÅHûev÷qì÷›v°é-òÄ÷%÷[÷'ö÷^øaû%ıG÷%÷‘w­·´÷åì÷(î÷-ñûYb|ib0§¯¢”ªĞ³X35_UDnq” n÷,‹÷øD÷Ö÷>÷á÷CÖù>ı>÷®÷¤÷÷$÷X÷Oû÷/ûûû÷÷5Ê(û	'Xûû?ûü vøawå÷4Â÷4û,÷%è÷døaû%üa÷%0BùG_gg__¯g··¯¯··g¯_H‚ì3ãø	wÇ÷%÷A÷%xø÷%øaû&¸ûº^|ci_eh¢Ì÷±û%û»ûÙSæÅ¸¡À¹÷È vø	ì‚wÊ÷%÷[÷%÷[÷%¼÷døaû%üa÷%Ü÷Éµ®±¡±¶¸r@û¥÷%÷»¾¬²¦µÀ«fIû¢÷%÷¼ô@Ğ"FVnFOÍkU«;np†€p¼qqzrt÷—vøjwŠù£ø÷†÷ûĞ÷cøjû(*û’%÷’3$û’*÷’û(÷düjÏH vø õ÷hwÉ÷%÷@÷%÷cù>û%ı>÷%÷º¼­¨ ­¸©kFû›÷%÷º÷6¾7R\sVa‰÷7‚÷"ó÷÷O÷"º÷C÷÷“û0÷>øùkù¬G(¢%û‡û<û#ûdû`÷=û%÷‚ô÷÷²À¾÷«øû¡ûôî;wYv‡aû!,Û÷ğÌ÷÷Møßßvaâ‚”ù>”ûz”÷Š—÷Ù’üÆ”î
Œ
yXO	÷ªù
endstream
endobj
23 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 65/A 67/C 69/E 79/O/P 82/R/S/T]/Type/Encoding>>
endobj
25 0 obj
<</Ascent 716/CapHeight 682/Descent -230/Flags 32/FontBBox[-162 -230 1041 911]/FontFile3 24 0 R/FontName/LORKSW+GillSans/ItalicAngle 0/StemH 0/StemV 89/Type/FontDescriptor/XHeight 728>>
endobj
24 0 obj
<</Length 850/Length1 850/Subtype/Type1C>>stream
  LORKSW+GillSans   @ø øøøøû6ûzú¥ú#
 ‹‹
 ‹‹   î   ê  ·  & |…Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corpration Plc.Gill Sans    $ " 4 &  3 1 0 5 
   M „ Ø\˜ïüÅ‚åøœå»ğù$ù².DœEûmû1û,ûdû#÷ûY÷”öÔ¤®ÎöY>7p>û8ûõ÷-÷*÷÷÷0ÚÓuZßœ v÷]ãø!w‹ù/÷şùBFû¹ıBïá÷]÷¶æû]ïûéø¬÷û‹ûhûT‚ãø ã³æ÷`æø#ù«[W›Wû9DûûO÷»{‹û!eh[?HL®ËYû`ÄÇwÕ÷ÜÙö÷mû»‰‹÷»¸¬Ê¹Ã{TÅû*‹ã÷hã÷bãÖíøbù>üı>ø ãû¾÷h÷«ãû«÷b÷µü] v÷¼ã÷jßØí÷YğØù>ı>í÷¼´½´{û ååû ÷	\Ìz¢nºWàeÊM´Ô¨´Æ‹Ú‹÷
5Ôû‹A7Êê±dKŒRŒmU"Lû  v÷»ã÷gãÑí÷{ğÑù>ı>í÷»ñ÷2Óßö÷ Gãû)û3÷ä¦UYG\dBû÷A‚åøœå¸ğø§ğ¸÷éûM÷!û9÷s÷{÷÷:÷L÷Rû"÷4ûuûqû%û5ûQğ÷*÷÷÷,÷-÷ûû*û)ûûû-û,û÷÷)] vøæã÷‘íøßù>üÎ3÷€üæíøæ÷€•ù>—û‰”÷–—÷ÛüÆ‹Û
äZ 

yXO	÷ªù
endstream
endobj
67 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
68 0 obj
<</OP false/OPM 0/op false>>
endobj
100 0 obj
<</A 101 0 R/Border[0 0 0]/Rect[259.007 9.0 300.752 16.0]/Subtype/Link/Type/Annot>>
endobj
101 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
63 0 obj
<</CreationDate(D:20080123145847Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20150418043643-07'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 102
0000000000 65535 f
0000042249 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000029411 00000 n
0000029841 00000 n
0000029634 00000 n
0000017173 00000 n
0000033313 00000 n
0000033602 00000 n
0000033399 00000 n
0000017019 00000 n
0000033857 00000 n
0000034289 00000 n
0000034081 00000 n
0000016635 00000 n
0000124949 00000 n
0000125269 00000 n
0000125067 00000 n
0000118425 00000 n
0000058305 00000 n
0000058870 00000 n
0000058667 00000 n
0000057646 00000 n
0000018603 00000 n
0000019346 00000 n
0000019141 00000 n
0000017823 00000 n
0000064557 00000 n
0000065033 00000 n
0000064820 00000 n
0000057202 00000 n
0000122139 00000 n
0000122538 00000 n
0000122326 00000 n
0000118690 00000 n
0000120271 00000 n
0000120639 00000 n
0000120428 00000 n
0000119071 00000 n
0000119581 00000 n
0000119881 00000 n
0000119668 00000 n
0000119430 00000 n
0000037818 00000 n
0000038235 00000 n
0000038020 00000 n
0000016241 00000 n
0000001882 00000 n
0000001970 00000 n
0000002288 00000 n
0000002557 00000 n
0000002838 00000 n
0000003107 00000 n
0000003388 00000 n
0000000016 00000 n
0000126457 00000 n
0000000097 00000 n
0000107681 00000 n
0000107707 00000 n
0000126196 00000 n
0000126254 00000 n
0000018514 00000 n
0000094849 00000 n
0000094874 00000 n
0000107423 00000 n
0000107481 00000 n
0000083865 00000 n
0000083890 00000 n
0000094591 00000 n
0000094649 00000 n
0000069863 00000 n
0000069888 00000 n
0000083607 00000 n
0000083665 00000 n
0000042548 00000 n
0000042573 00000 n
0000069605 00000 n
0000069663 00000 n
0000003645 00000 n
0000003670 00000 n
0000042290 00000 n
0000042348 00000 n
0000042393 00000 n
0000042492 00000 n
0000069708 00000 n
0000069807 00000 n
0000083710 00000 n
0000083809 00000 n
0000094694 00000 n
0000094793 00000 n
0000107526 00000 n
0000107625 00000 n
0000126299 00000 n
0000126400 00000 n
trailer
<</Size 102/Root 62 0 R/Info 63 0 R/ID[<AC7E45C73F2CD577463BA47748C58553><C20427E3D11DB2110A001A0A10000000>]>>
startxref
126685
%%EOF
